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Multicomponent reactions provide simple and convergent paths to structurally 
complex products in atom-economical fashion. With the emergence of combinatorial 
chemistry and high-speed parallel synthesis, MCR chemistry has experienced a 
resurgence of interest in the past two decades. However, the application of MCRs is 
still largely limited by the relatively small number of such reactions. 
As part of our effort to synthesize new molecular frameworks by using the 
“single reactant replacement” (SRR) strategy to evolve existing MCRs, we have 
explored the chemistry and reactivity of several α-substituted ketones (sulfonyloxy, 
acyloxy, azido, halo, hydroxyl and sulfonyl) in the two most utilized isonitrile-based 
multicomponent reactions, the Passerini and Ugi reactions.  
Guided by SRR, highly convergent routes to oxazoline, β-lactam, di-O-
acylglyceramides, and other molecular frameworks were developed. In a relative rate 
study, each of the α-substituted ketones underwent Passerini condensation more 
rapidly than the parent ketone, which was consistent with the expected enhancement 
of carbonyl electrophilicity caused by electronegative substituents. 
 Using the Passerini reaction, a multicomponent approach was developed 
leading to photolabile caged neurotransmitter, 7-(N,N-diethylamino)-4-
(hydroxymethyl) coumarin (DECM) caged gamma-aminobutyric acid. Another caged 
neurotransmitter, DECM caged carbamoylcholine chloride, was synthesized in a 
highly convergent one-pot process.
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CHAPTER ONE 
Development of Isonitrile-Based Multicomponent Reactions 
 
 
 
 
 
 
 
 
 
 
 1
1.1 Background 
The ability to create complex molecules in a general and efficient manner has 
long challenged organic chemists. A good example of such an endeavor is the one-pot 
assembly of the bridged bicyclic alkaloid tropinone by Robert Robinson (Scheme 
1.1).1 This highly efficient synthesis was achieved by minimizing steps while 
maximizing structural and functional complexity. 
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Scheme 1.1 Synthesis of Tropinone by Robinson 
Because of increasing economic pressure and environmental concerns in the 
chemical and pharmaceutical industry, efficiency is now especially desirable in 
synthetic design. Among various ways to enhance synthetic efficiency, the used of 
multicomponent reactions constitutes a very attractive strategy. 
A multicomponent reaction (MCR) is generally defined as a one-pot chemical 
process that affords one product from the combination of three or more reactants.2 By 
forming multiple bonds in a single chemical operation, MCRs offer excellent 
synthetic efficiency. Other advantages over conventional bimolecular reactions 
include high selectivity, high atom-economy, convergence, and operational simplicity.  
Overall MCRs represent a big step towards Wender’s concept of ideal synthesis, 
which “can be measured by parameters such as the step count, overall yield, 
selectivity, cost, scale, resource requirements, waste stream, development time, and 
execution time”.3
MCRs are appealing in both target-oriented and diversity-oriented synthesis. 
Their convergence and high productivity can save operational time and cost in all 
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areas of applied synthesis. By virtue of their exploratory and complexity-generating 
power, MCRs are ideal tools with which large collections of structurally diverse 
compounds, also known as libraries, can be built. Screening such libraries has had 
enormous implications for the discovery of small molecules with desired properties, 
such as pharmaceutical reagents, synthetic compounds, biological probes and new 
catalysts.4 
The first widely-recognized MCR was developed by Strecker in 1850.5 The 
Strecker reaction enables the synthesis of α-amino acids via α-amino nitriles. Several 
other historically significant MCRs are listed in Table 1.1.  Robinson’s synthesis is, in 
fact, an ingenious application of the Mannich reaction.  
With the introduction of high-throughput biological screening during 1990s, 
the demand for the number and quality of compounds used in drug discovery has 
increased dramatically. Driven by these challenges, MCR research evolved rapidly 
after 1995.14 Many new and synthetically useful MCRs and variations have been 
developed to access hundreds of natural product-like or drug-like scaffolds. 
Furthermore, the combination of MCRs with other transformations has also flourished, 
providing even more structural diversity. Some significant achievements are listed in 
Table 1.2.  
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Table 1.1 Some Historically Significant MCRs  
 
Name Year Example  
Strecker 
synthesis 1850 
 
5
Hantzsch 
dihydro-
pyridine 
synthesis 
1882 
 
6
Hantzsch 
pyrrole 
synthesis 
1890 
 
7
Biginelli 
reaction  1891 
 
8
Mannich 
reaction 1912 
 
9
Passerini 
reaction 1921 
 
10
Bucherer-
Bergs 
synthesis 
1945 
R
O
H
HN NH
O
O R
NH3 C OOHCN
 
11
Ugi 
reaction 1959 
 
12
Gewald 
reaction  
1961 
 
13
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Table 1.2 Applications of MCRs  
 
Name  Synthesis  Ref 
Xylocain, 
by Ugi 
reaction 
 
 
 
12 
 
 
 
Monastrol 
by 
Biginelli 
reaction 
 
 
 
 
15 
 
 
 
Nifedipine 
by Hantsch 
reaction 
 
NH3
O
COOEt
N
H
EtOOC COOEtO
COOEt
NO2
CHO
NO2
 
 
 
 
6 
 
 
 
Piperazine-
2-carbox- 
amide, core 
structure of 
Crixivan, 
by Ugi-
4CR. 
 
 
 
 
16 
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1.2 Isonitrile-Based Multicomponent Reaction (IMCR) Chemistry 
IMCRs constitute an extremely powerful subclass of MCRs.  IMCRs rely on 
the unusual valence structure of isonitriles. The isonitrile functional group can be 
considered as a synthetic equivalent of vinylidene carbene, in which CII is oxidized to 
CIV in exothermic reactions.17 The two most widely utilized MCRs, the Passerini and 
Ugi reactions, are both IMCRs.  
The Passerini three-component reaction (Passerini 3CR) was originally 
described in 1921 by Mario Passerini.10 The reaction enables the synthesis of α-
acyloxy-carboxamides by combining a carboxylic acid, an aldehyde or ketone, and an 
isonitrile in one step. A plausible mechanism involves a sequence of 1) activation of 
the carbonyl group by partial hydrogen bonding, 2) α-addition of the isonitrile to the 
activated carbonyl compound and the carboxylate anion, 3) intramolecular Mumm 
rearrangement (Scheme 1.2).  
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R2O
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R1 H
O
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C N R3
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OR1 H
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N
R3
R2
O
O
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O
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H
R3
H
N
R1
O
O
R2
O
 
 
 
 
 
 
 
 Scheme 1.2 Mechanism of the Passerini 3CR 
The Ugi four-component reaction (Ugi 4CR) converts an aldehyde or ketone, 
an amine, an acid and an isonitrile into an α-acylamino amide in one step, with good 
to excellent yields.12 The mechanism involves imine formation, protonation of the 
imine followed by α-addition and Mumm rearrangement. As illustrated, the Ugi 
reaction has strong mechanistic similarities to the Passerini 3CR (Scheme 1.3).  
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 Scheme 1.3 Mechanism of the Ugi 4CR 
The Passerini and Ugi reactions are both robust reactions with excellent 
substrate scope and versatility. They are straightforward to perform and afford 
products in high yields with good purities. In fact, the large number of different 
molecular frameworks now available by MCR chemistry builds mostly on these two 
IMCRs and their combination with other reactions.18  
1.3 Evolving Existing MCRs: Single Reactant Replacement 
As powerful as MCRs are, their synthetic applications are still largely 
constrained by the number of available MCRs. The need to invent new MCRs, 
through which new scaffolds can be accessed, has stimulated research in new reaction 
discovery. Mainly four approaches have been described: random discovery, 
combinatorial chemistry, discovery by design, and union of MCRs.19   
Our approach is a mechanism-based discovery strategy called single reactant 
replacement (SRR).2 In SRR, one component of a known MCR is replaced with a 
component bearing an orthogonal reactivity element. The additional functionality 
undergoes subsequent reaction to redirect the reaction outcome, either spontaneously 
or upon treatment with additional reagents. Synthetic possibilities are hence increased 
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and ring systems may be prepared via intramolecular cyclization with appropriate 
substituents. 
When evolving a known MCR using the SRR approach, three factors need to 
be considered. Firstly, starting materials should be readily available to insure a wide 
reaction scope and utility. Secondly, the key reactivity element in the multicomponent 
condensation step needs to be retained or enhanced. Thirdly, the expected product 
should resemble one or more bioactive structures.   
Guided by SRR, our laboratory has made several discoveries over the years. 
Xia et al. investigated the effect of replacing the carboxylic acid component of the 
Passerini reaction with Lewis acids. 20 As a result, α-hydroxyamides and substituted 
oxazoles were synthesized by condensations of carbonyl compounds with 
appropriately substituted isonitriles capable of neighboring group donation (Scheme 
1.4).  
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 1.4 Passerini Reaction with Lewis Acids 
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Oaksmith et al. discovered that by replacing the carbonyl compounds in the 
Passerini reaction with acylnitriles, β-aminoacid diamides were formed instead of the 
conventional α-acyloxyamides (Scheme 1.5).21
 
 
 
 
Scheme 1.5 Syntheses of β-Aminoacid Diamides via P-3CR 
 
The application of acylnitriles in the Passerini reaction was further expanded 
by Clemençon et al. By combining the Passerini reaction with post-condensation 
dipolar cycloaddition reactions using either diazomalonic esters or alkyl azides, acyl 
nitriles were conveniently converted into 1,3-oxazoles or tetrazoles, respectively 
(Scheme 1.6).22  
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Scheme 1.6 Tandem MCR 
 
 
1.4 IMCRs with α-Substituted Ketones 
In continuing our group’s efforts to evolve existing MCRs and to synthesize 
new molecular frameworks, we investigated α-substituted ketones as surrogates for 
simple carbonyl compounds in the Passerini and Ugi reactions.  
Several reasons led us to study α-substituted ketones. Many α-substituted 
ketones are conveniently accessible from the corresponding acid chlorides. Moreover, 
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the Passerini and Ugi reactions with regular ketones are often sluggish because of the 
lack of reactivity at the carbonyl group. By adding an electron-withdrawing 
substituent at the α-position, the reactivity of the α-substituted ketone to nucleophilic 
addition is expected to increase. Finally, biologically important molecular scaffolds, 
including heterocycles, might be assembled.  
A comprehensive literature review showed that prior to our own study, there 
were few reports of Passerini of Ugi condensations on α-substituted ketones. The only 
example found was Sebti’s use of α-chloroketones in a Passerini condensation to 
prepare chloro-substituted acyloxyamides, which were then transformed into acyoxyl-
β-lactams when treated with sodium hydride.23  
 Several reactive α-substituents were of potential interest, including 
sulfonyloxy, acyloxy, azido, halo, hydroxyl and sulfonyl. In most cases, the starting 
material for α-substituted ketones was the corresponding α-diazoketone, which was 
available by reaction of the cognate acid chloride with diazomethane (Scheme 1.7). 
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Scheme 1.7 Preparation of α-Substituted Ketones 
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Interestingly, α-diazoketones were found to be resistant to Passerini and Ugi 
conditions. The lack of reactivity was likely due to the resonance stabilization of the 
carbonyl group by the diazo group. Mesyloxy and tosyloxyketones 2 and 3, 
respectively, proved to be excellent carbonyl components in the Passerini and Ugi 
reactions. As described in Chapter 4, the expected products 9 were formed in the 
Passerini reaction of 2 and 3. Compound 9 was further converted to substituted β-
lactams 10 upon treatment with NaH. In Chapter 2, substituted 2-oxazolines 11 were 
prepared in an efficient and general one-pot, four-component condensation in the Ugi 
reaction with ammonia (Scheme 1.8).2, 23 
 
 
 
 
 
2,3
R2CO2H
CNR3 R1 CH2OMs(Ts)
OCOR2
O NHR3
9
NaH R1
OCOR2
O
N
R3
10
 
 
Scheme 1.8 Preparation of β-Lactams 10 and Oxazoline 11 
 
Chapter 3 reports the study of the reactivity of diazocarbonyls to carboxylic 
acids using transition metal catalysis. A one-pot, four-component condensation was 
achieved to furnish substituted di-O-acylglyceramides 12 from α-diazoketones 
(Scheme 1.9).24 
 
 
 11
 1
R3CO2H
CNR4R2CO2H
Cu(acac)2
R1
O
CO2R2
R1 CH2OCOR3
OCOR2
O NHR4  
12 
 
 
Scheme 1.9 Preparation of Substituted Di-O-acylglyceramides 12 
 
The relative rates of reaction of various α-substituted ketones were studied in a 
representative Passerini condensation with acetic acid and t-butyl isonitrile under neat 
conditions at rt. (Chapter 4) The kinetic data were consistent with the expected 
enhancement of carbonyl electrophilicity caused by eletronegative substituents. The 
rate differences suggest of that chemoselective Passerini reaction could be achieved 
with certain α-substituted ketones. 
In conclusion, the chemistry and reactivity of a broad range of α-substituted 
ketones in the Passerini and Ugi reactions were studied. The utility of these two 
powerful name reactions was significantly enhanced, and new dimensions were added 
to the chemical space accessible by these reactions. As new reactions and 
methodologies continue to emerge, the impact of MCRs on synthetic chemistry is 
expected to grow in the future. 
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CHAPTER TWO 
Bioactive 2-Oxazolines: A New Approach via One-Pot,  
Four-Component Reaction 
ABSTRACT 
Reproduced in part with permission from  
Organic Letters, 2007, Vol. 9, No. 10, 2015 – 2017 
Copyright © 2007 by the American Chemical Society  
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2.1  Introduction 
Oxazolines are widely used in polymer chemistry as synthetic reagents and 
most recently as ligands in asymmetric synthesis.1 Alkyl- and aryl-substituted 2-
oxazolines are also present in marine natural products2 and are important 
pharmacophores in numerous  bioactive natural products that display cytotoxic, 
antitumor, neuroprotective, antibiotic, or antifungal properties.  
Some representative examples (Figure 2.1) include the cytotoxic agent 
brasilibactin 1,3 a family of five antitumor substances represented by B32030A 2 and 
B32030B 3,4 and the recently discovered T-cell antigen didehydroxymycobactin 
3, a complex lipopeptide related to the mycobactin family of mammalian siderophores 
that utilize the 2-hydroxyphenyloxazoline carboxamide substructure (box) to sequester 
iron in macrophages.5  
 
 
 
 
 
 
 
O
N
R2
O
N
OHR1 O
O
R4
R5
O
N
(CH2)2NXCOR3
O
X
1,X=OH; R1-R3=H; R4,R5=CH3 brasilibactin A
3,X=H; R1,R5=H; R4=CH3; R3=cis-CH=CH-(CH2)16CH3
didehydroxymycobaction
2,X=OH; R2,R4, R5=H; R4=CH3; R3=n-C12H25
R1=H (BE-32030A) or R1=OH (BE-32030D)
H
Figure 2.1 Substituted 2-Oxazolines in Bioactive Natural Products. 
 
We have been interested in developing convergent synthetic routes to such 
complex oxazolines utilizing a multicomponent reaction to assemble the key 
heterocyclic pharmacophore in a single flask. Here, we report a powerful and versatile 
4-component condensation that efficiently produces 2-substituted oxazoline-4-
carboxamides and their congeners as highlighted in 1-3 in good yields.  
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The approach we envisioned was based on the known biosynthesis of many 
peptide-derived oxazolines, which usually involves cyclization of N-acyl serine 
residues. We initially considered an Ugi reaction using α-diazoketones (readily 
prepared from acid chlorides using CH2N2) in place of simple aldehydes or ketones. 
However, mixtures of α-diazoketones, amines, isonitriles, and carboxylic acids proved 
unreactive, even when heated to 60-70 °C. 
2015-2017We therefore investigated Ugi condensations of the corresponding (and 
much more electrophilic) α-ketomesylates 4 (Scheme 2.1), which are readily available 
by the known insertion reaction6 of diazoketones with CH3SO3H. Our expectation was 
that if imine formation at the carbonyl group in 4 using ammonia were faster than 
displacement of the mesylate, then the intermediate diamide 5 might spontaneously 
cyclize in situ to the desired oxazoline 6.  
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Scheme 2.1 Proposed MCR Approach to Substituted 2-Oxazolines 
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2.2  Result and Discussion 
Using the β-ketomesylate 4a (Scheme 2.2) as a test case, a solution of 4a in 
CH3OH was stirred with NH3 and benzoic acid (1 equiv each) for 30 min at 0 °C. 
After adding cyclohexylisonitrile (1.1 equiv) then stirring at rt for 24 h, solvent 
evaporation led directly to roughly equal quantities of the target oxazoline 6a together 
with the corresponding three-component Passerini product 7a. Increasing the 
quantities of ammonia and benzoic acid slightly improved the yield of 6a but did not 
suppress formation of 7a. A more dramatic improvement was achieved by replacing 
methanol as solvent with 2,2,2-trifluoroethanol, which has been shown to improve Ugi 
reactions involving ammonia.7 Under optimal conditions (4 equiv each of NH3, 
PhCO2H), 6a was obtained in 61% yield (mp 89 °C) accompanied by ca. 5% of 7a. 
Interestingly, no products derived from simple nucleophilic substitution of the 
mesylate group in 4a were observed. 
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Scheme 2.2 One-Pot Synthesis of 2-Oxazolines 
 
 
The X-ray crystal structure of 6a confirmed the presence of the 2,4,4-
trisubstituted oxazoline ring. (Figure 2.2) 
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Figure 2.2 ORTEP Diagram of the X-ray Crystal Structure of Oxazoline 
6a. Hydrogen atoms are omitted for clarity. Selected bond distances (Å) 
and angles (deg): N(1)-C(18) ) 1.270(3), O(1)-C(18) ) 1.369(3), C(1)-
N(1) ) 1.474(3), O(1)-C(17) ) 1.444(3);N(1)-C(1)-C(17) ) 104.45(18), 
N(1)-C(18)-O(1) ) 118.5(2), C(18)-O(1)-C(17) ) 105.55(18), C(10)-
C(1)-C(17) ) 110.7(2), C(10)-C(1)-C(2) ) 106.70(19). 
 
Several examples of trisubstituted 2-oxazolines prepared by this four-
component condensation illustrate the scope and generality of the method (Table 2.1). 
Precondensing the carboxylic acid ammonium salt (4 equiv) and the ketomesylate in 
CF3CH2OH for 30 min at 0 °C is sufficient to minimize the formation of Passerini 
products like 7.  
 
 19
Table 2.1 Synthesis of 2-Oxazolines 6 from Ketomesylates 4  
 
ketomesylate 
4a-e 
R2CO2H 
R2 =　　 
R3NC 
R3 = 
Product   
(% yield) 
4a, R= Ph(CH2)2 C6H5 cyclohexyl 6a(61) 
 CH3 cyclohexyl 6b (71) 
 CH3 tert-butyl 6c (73) 
 Boc-(S)-Phe  cyclohexyl 6d (64)a
4b, R = n-C7H15b i-C3H7 CH2CO2Et 6e (60) 
 CH3 tert-butyl 6f (80) 
 Cbz-Gly tert-butyl 6g (38) 
4c, R = cyclohexyl CH3 CH2CO2Et 6h (63) 
 i-C3H7 tert-butyl 6i (60) 
4d, R = Phb CH3 tert-butyl 6j (63) 
4e, R = CH3c CH3 tert-butyl 6k (60) 
 C6H5 CH2CO2Et 6l (68) 
 o-(OH)C6H4 tert-butyl 6m (58)d
 o-(OH)C6H4 CH2CO2Et 6n (63)d,e
    
a Obtained as a mixture of diastereomers. b Cho, B. T.; Yang, W. K.; Choi, O. K. J. 
Chem. Soc. Perkin Trans. 1 2001, 1204. c Lodaya, J. S.; Koser, G. J. Org. Chem. 1988, 
53, 210. d CH3OH was used as solvent in this reaction. e 2 equiv of isonitrile was used 
in this reaction. 
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As the examples in Table 2.1 indicate, a broad range of carboxylic acids and 
isonitriles (including examples of both compound families derived from naturally 
occurring α-amino acids) underwent smooth reaction with various ketomesylates and 
ammonia to form the desired 2-oxazolines. Even resonance-stabilized ketomesylates 
such as PhCOCH2OMs 4d were reactive enough to form the desired oxazoline 
carboxamides, e.g., 6j, in good yield. 
When ammonia was replaced with a primary amine, such as benzyl or 
allylamine, the multicomponent reaction took a different course, affording aminoesters 
like 9a (Scheme 2.3) as the exclusive product from ketomesylate 4a. The structure of 
9a, which was also confirmed by single-crystal X-ray diffraction analysis, most likely 
arose via hydrolysis of an intermediate oxazolinium ion like 8a. Interestingly, none of 
the isomeric amido alcohol 10a was detected. 
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Scheme 2.3 MCR Route to Aminoester 9a from 4a 
 
The new oxazoline synthesis could also be applied (Scheme 2.4) to a one-pot 
assembly of the 2-hydroxyphenyl-4-methyloxazoline-4-carboxamide substructure 
found in natural products like 1-3. Initial attempts using salicylic acid as the 
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carboxylic acid component failed in trifluoroethanol because of the insolubility of 
ammonium salicylate. However, the problem was overcome by switching to methanol 
as solvent. Gratifyingly, the desired oxazoline 6n was produced in 63% yield. 
Furthermore, no phenol protecting group was required, in contrast to earlier total 
synthesis efforts in the mycobactin series.8 
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Scheme 2.4 Assembly of 2-Oxazoline Substructures in 1-3 
 
2.3  Conclusion 
In summary, we have developed an efficient four component reaction that 
affords 2-substituted oxazoline-4-carboxamides in a one-pot process from readily 
available starting materials. With their widespread occurrence in bioactive natural 
products, such functionalized oxazolines may be considered privileged structures, i.e., 
molecular frameworks exhibiting medicinally useful binding properties. The 
multicomponent synthesis reported here rapidly assembles promising lead compounds 
containing this heterocyclic system for use in drug discovery endeavors. 
2.4  Experimental Procedures  
Melting points were uncorrected. 1H NMR and 13C NMR were taken on a 
Varian Mercury-300, Varian Inova-400 or Varian Inova-500 spectrometer as indicated 
using CDCl3 with 0.05% v/v TMS as solvent. Spectra were recorded in δ (ppm) and 
were referenced to TMS (0.00 ppm for 1H NMR) and CDCl3 (77.23 ppm for 13C 
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NMR). IR spectra were obtained on a Mattson Instruments Galaxy Series FT-IR 
spectrometer and were recorded in wavenumbers (cm-1). Chemicals were obtained 
from Aldrich, Fluka, Fisher, Lancaster, Mallinckrodt, or Novabiochem and used as 
received unless specified. Ether was distilled from sodium/benzophenone. Methanol 
and 2,2,2-trifluoroethanol was distilled from CaH2. In reactions leading to 
diastereomers, spectroscopic data were reported for mixtures, unless specified 
otherwise. 
Synthesis of ketomesylates 4a and 4c from diazoketones and methanesulfonic 
acid. 
1-Mesyloxy-4-phenyl-2-butanone 4a: To methanesulfonic acid (3.85 mmol) in 
anhydrous ether (10 mL) at 0 °C, was slowly added a solution of 1-diazo-4-phenyl-2-
butanone (3.5 mmol) in anhydrous ether (5 mL) by syringe over a 10 min period. The 
reaction mixture was stirred for 10 min at 0 °C, then 10 min at rt. Water (10 mL) was 
then added with stirring for 30 min at rt. After separating the layers, the aqueous phase 
was extracted with ether (3 x 10 mL) and the combined ether layers were washed with 
H2O (3 x 10 mL) and saturated NaCl (10 mL), dried over MgSO4, filtered, and 
concentrated in vacuo. The crude product was purified by silica gel flash column 
chromatography (3:7 hexanes: ethyl acetate, Rf= 0.2), to afford the desired product as 
a white solid (0.7 g, 83%): mp 56-57 °C; 1H NMR (400 MHz, CDCl3) δ 7.17-7.32 (m, 
5H), 4.72 (s, 2 H), 3.16 (s, 3 H), 2.95 (t, 2 H, J= 7.4 Hz), 2.80 (t, 2 H, J= 7.4 Hz); 13C 
NMR (100 MHz, CDCl3) δ 202.31, 140.18, 128.88, 128.49, 126.70, 71.80, 40.42, 
38.96, 29.26; IR (CH2Cl2) 3055(s), 1742(s), 1360(s), 1179(s); CIMS (methane) m/z 
243(M+H), 219, 147, 129.  
(Mesyloxyacetyl)cyclohexane 4c: The crude product was purified by silica gel flash 
column chromatography (3:7 hexanes:ethyl acetate, Rf=0.3), to afford the desired 
product as white solid (97% yield): mp 71°C; 1H NMR (400 MHz, CDCl3) δ 4.89 (s, 2 
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H), 3.21 (s, 3 H), 2.44 (m, 1 H), 1.80 (t, 4 H, J=12.1 Hz), 1.70 (br d, 1 H, J=10.5 Hz), 
1.2-1.4 (m, 5 H); 13C NMR (100 MHz, CDCl3) δ 205.99, 71.11, 47.53, 39.59, 28.57, 
26.06, 25.86; IR (CH2Cl2) 3055(s), 2938(s), 1732(s), 1356(s), 1177(s); CIMS 
(methane) m/z 221(M+H), 125, 107.  
Representative procedure for the synthesis of 2-substituted oxazoline-4-
carboxamides 6a-n. 
Compound 6a: To a solution of 4a (0.2 mmol) in anhydrous 2,2,2-trifluoroethanol (0.5 
mL) at 0 oC was added ammonium benzoate (0.8 mmol).  The reaction mixture was 
stirred for 30 min at 0 °C, then cyclohexyl isocyanide (0.22 mmol) was added via 
syringe with stirring. The reaction mixture was warmed to rt and stirred for 18 h. The 
solvent was evaporated under reduced pressure to give an oil. The crude product 
obtained was purified by silica gel flash column chromatography (3:7 hexanes: ethyl 
acetate, Rf= 0.5) to afford 6a as a white solid (48 mg, 61%): mp 89 °C: 1H NMR (400 
MHz, CDCl3) δ 8.0 (m, 2 H), 7.14-7.55 (m, 8 H), 6.72 (d, 1 H, J= 8.4 Hz), 4.64 (d, 1 
H, J= 9.1 Hz), 4.34 (d, 1 H, J= 9.1 Hz), 3.77 (m, 1 H), 2.81 (td, 1 H, J= 13.2, 4.6 Hz), 
2.59 (td, 1 H, J= 13.2, 4.6 Hz), 2.30 (td, 1 H, J= 13.1, 5.0 Hz), 1.96-2.06 (m, 2 H), 
1.83-1.86 (m, 1 H )1.58-1.75 (m, 3 H ), 1.11-1.44 (m, 5 H); 13C NMR (100 MHz, 
CDCl3) δ 172.97, 164.35, 141.39, 131.77, 128.40, 128.33, 128.29, 128.25, 127.21, 
125.77, 77.58, 75.13, 47.75, 41.41, 33.08, 32.78, 30.02, 25.38, 24.69; IR (CH2Cl2) 
3387(s), 2934(s), 1666(s), 1647(s), 1516(s), 1452(s); CIMS (methane) m/z 377 (M+H), 
250, 179.  
 Also obtained was a small quantity of the corresponding Passerini reaction 
product 7a as a white solid (5% yield), which was purified by silica gel flash column 
chromatography (3:7 hexanes: ethyl acetate, Rf= 0.2) and shown to be identical to an 
authentic sample prepared by the reaction of 4a with benzoic acid and cyclohexyl 
isocyanide: mp 105-110 °C 1H NMR (400 MHz, CDCl3) δ 7.12-7.94(m, 10 H), 6.45 (d, 
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1 H, J= 8.6 Hz), 5.16 (d, 1 H, J= 10.0 Hz), 4.71 (d, 1 H, J= 8.9 Hz), 3.89 (m, 1 H), 
2.94 (s, 3H), 2.56-2.70 (m, 3 H), 2.40-2.45 (m, 1 H), 1.96-2.06 (m, 2 H), 1.72-1.77 (m, 
2 H ), 1.62-1.66 (m, 1 H ), 1.38-1.46 (m, 2 H ), 1.22-1.29 (m, 3 H); 13C NMR (100 
MHz, CDCl3) δ 167.79, 164.73, 140.19, 133.96, 129.82, 129.64, 128.98, 128.67, 
128.53, 126.44, 85.47, 70.01, 48.78, 37.33, 33.60, 33.19, 32.99, 29.62, 25.57, 24.83, 
24.77; IR (CH2Cl2) 3443(m), 3055(s), 2937(m), 1730(s), 1680(s), 1520(s), 1364(s); 
CIMS (methane) m/z 474 (M+H), 378, 256. 
Compound 6b: The crude product was purified by silica gel flash column 
chromatography (3:7 hexanes: ethyl acetate, Rf= 0.3) to afford 6b as a white solid 
(71% yield): mp 135 °C; 1H NMR (400 MHz, CDCl3) δ 7.16-7.28 (m, 5 H), 6.58 (d, 1 
H, J= 8.1 Hz), 4.46 (d, 1 H, J= 9.3 Hz), 4.26 (d, 1 H, J= 9.3 Hz), 3.77 (m, 1 H), 2.75 
(td, 1 H, J= 13.1, 4.8 Hz), 2.53 (td, 1 H, J= 12.8, 4.9 Hz), 2.20 (td, 1 H, J= 13.1, 4.8 
Hz), 2.05 (s, 3 H), 1.90 (m, 3 H), 1.71 (m, 2 H), 1.60 (m, 1 H), 1.38 (m, 2 H), 1.22 (m, 
3 H); 13C NMR (125 MHz, CDCl3) δ 173.20, 166.49, 141.58, 128.58, 128.56, 126.12, 
77.59, 75.50, 48.11, 41.69, 33.36, 33.09, 30.32, 25.66, 25.03, 24.99, 14.43; IR 
(CH2Cl2) 3354(s), 2936(s), 1649(b, s), 1502(s); CIMS (methane) m/z 315 (M+H), 234, 
206, 100. 
Compound 6c: The crude product was purified by silica gel flash column 
chromatography (3:7 hexanes: ethyl acetate, Rf= 0.4) to afford 6c as a clear oil (73% 
yield): 1H NMR (400 MHz, CDCl3) δ 7.15-7.29 (m, 5 H), 6.52 (s, 1 H), 4.45 (d, 1 H, 
J= 9.2 Hz), 4.10 (d, 1 H, J= 9.2 Hz), 2.72 (td, 1 H, J= 13.4, 4.7 Hz), 2.51 (td, 1 H, J= 
12.8, 4.7 Hz), 2.19 (td, 1 H, J= 13.1, 4.9 Hz), 2.05 (s, 3 H), 1.88 (td, 1 H, J= 13.1, 4.8 
Hz), 1.37 (s, 9 H); 13C NMR (100 MHz, CDCl3) δ 173.40, 166.29, 141.71, 128.60, 
128.59, 126.12, 77.85, 75.47, 51.19, 41.78, 30.33, 28.95, 14.47; IR (CH2Cl2) 3381(s), 
2968(s), 1672(s), 1518(b, s); CIMS (methane) m/z 289 (M+H), 233, 188.  
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Compound 6d: (diastereomers) The crude product was purified by silica gel flash 
column chromatography (3:7 hexanes: ethyl acetate, Rf= 0.4) to afford 6d as a clear oil 
(64% yield): 1H NMR (400 MHz, CDCl3) δ 7.06-7.30 (m, 10 H), 6.45 (d, 0.5 H, J= 8.1 
Hz), 6.31 (d, 0.5 H, J= 8.1 Hz), 5.02 (d, 1 H, J= 7.5 Hz), 4.70 (t, 1 H, J= 5.8 Hz), 4.51 
(d, 0.6 H, J= 9.0 Hz), 4.45(d, 0.4 H, J= 8.8 Hz), 4.18 (d, 0.4 H, J= 8.8 Hz), 4.16 (d, 0.6 
H, J= 9.0 Hz), 3.70 (m, 1 H ), 3.10 (m, 2 H), 2.55 (m, 1 H), 2.39 (m, 1 H), 2.15 (m, 1 
H), 1.59-1.90 (m, 6 H ), 1.47 (s, 9 H), 1.03-1.47(m, 5 H ); 13C NMR (100 MHz, CDCl3) 
δ 172.61, 167.39, 155.21, 141.53, 135.92, 129.71, 129.62, 128.73, 128.61, 128.55, 
128.52, 128.50, 127.32, 127.22, 126.08, 80.29, 77.36, 77.34, 76.43, 76.05, 50.34, 
50.07, 48.24, 48.14, 41.40, 38.71, 38.33, 33.30, 33.23, 32.99, 30.29, 30.13, 28.58, 
28.55, 25.67, 25.08, 25.05; IR (CH2Cl2) 3431(w), 3055(s), 2935(s), 1712(s), 1664(s), 
1520(s); CIMS (methane) m/z 520 (M+H), 492, 464, 420.  
Compound 6e: The crude product was purified by silica gel flash column 
chromatography (3:7 hexanes: ethyl acetate, Rf= 0.5) to afford 6e as a clear oil (60% 
yield): 1H NMR (500 MHz, CDCl3) δ 7.15 (t, 1 H, J= 5.5 Hz), 4.38 (d, 1 H, J= 9.6 Hz), 
4.20 (dd, 2 H, J= 14.7, 7.2 Hz), 4.10 (d, 1 H, J= 9.3 Hz), 4.02 (ddd, 2 H, J= 19.1, 13.4, 
6.1 Hz), 3.60 (m, 1 H), 1.80 (m, 1 H), 1.67 (m, 2 H), 1.19-1.30 (m, 19H), 0.87 (t, 3 H, 
J= 7.1 Hz); 13C NMR (125 MHz, CDCl3) δ 175.46, 173.55, 169.71, 77.41, 74.71, 
61.62, 41.16, 39.16, 32.00, 29.82, 29.34, 28.56, 23.50, 22.83, 20.03, 19.91, 14.35, 
14.29; IR (CH2Cl2) 3398(m), 3055(s), 2931(s), 1745(s), 1674(s), 1520(s); CIMS 
(methane) m/z 341 (M+H), 210.  
Compound 6f: The crude product was purified by silica gel flash column 
chromatography (3:7 hexanes: ethyl acetate, Rf= 0.5) to afford 6f as a clear oil (80% 
yield): 1H NMR (400 MHz, CDCl3) δ 6.45 (s, 1 H), 4.40 (d, 1 H, J= 9.3 Hz), 4.05 (d, 1 
H, J= 9.3 Hz), 2.02 (s, 3 H), 1.79 (m, 1 H), 1.60 (m, 1 H), 1.35 (s, 9 H), 1.20-2.30 (m, 
10 H), 0.87 (m, 3 H); 13C NMR (100 MHz, CDCl3) δ 173.85, 165.86, 77.99, 75.46, 
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51.06, 39.86, 31.96, 29.84, 29.35, 28.94, 23.80, 22.81, 14.41, 14.28; IR (CH2Cl2) 
3381(m), 2930(s), 1670(s), 1520(s), 1265(s); CIMS (methane) m/z 283 (M+H), 227, 
182.  
Compound 6g: The crude product was purified by silica gel flash column 
chromatography (3:7 hexanes: ethyl acetate, Rf= 0.3) to afford 6g as a clear oil (38% 
yield): 1H NMR (400 MHz, CDCl3) δ 7.34-7.38 (m, 5 H), 6.35 (s, 1 H), 5.35 (s, 1 H), 
5.15 (s, 2 H), 4.49 (d, 1 H, J= 9.0 Hz), 4.12 (d, 1 H, J= 9.0 Hz), 4.05 (m, 2 H), 1.81 (m, 
1 H), 1.60 (m, 1 H), 1.35 (s, 9 H), 1.25-1.30 (m, 10 H), 0.87 (m, 3 H); 13C NMR (100 
MHz, CDCl3) δ 173.22, 165.06, 156.29, 136.38, 128.81, 128.53, 128.36, 77.45, 76.38, 
67.34, 51.19, 39.62, 38.82, 31.97, 29.79, 29.35, 28.89, 23.77, 22.83, 14.29; IR 
(CH2Cl2) 3441(m), 3055(s), 2930(s), 1726(s), 1670(s), 1522(s), 1265(s); CIMS 
(methane) m/z 432(M+H), 376, 324. 
Compound 6h: The crude product was purified by silica gel flash column 
chromatography (3:7 hexanes: ethyl acetate, Rf= 0.1) to afford 6h as a white solid 
(63% yield): mp 86-89 °C 1H NMR (400 MHz, CDCl3) δ 7.26 (s, 1 H), 4.34 (d, 1 H, 
J= 9.1 Hz), 4.24 (d, 1 H, J= 9.1 Hz), 4.22 (dd, 2 H, J= 6.9, 3.3 Hz), 4.03 (ddd, 2 H, J= 
18.1, 9.8, 5.9 Hz), 2.02 (s, 3 H), 1.61-1.79 (m, 6 H), 1.09-1.35 (m, 7 H), 0.89 (m, 1 H); 
13C NMR (125 MHz, CDCl3) δ 175.00, 169.74, 166.12, 81.14, 73.50, 61.63, 45.09, 
41.11, 27.48, 26.48, 26.40, 26.37, 26.22, 14.35, 14.23; IR (CH2Cl2) 3400(m), 3055(s), 
2933(s), 1745(s), 1670(s), 1520(s); CIMS (methane) m/z 297 (M+H), 251, 166. 
Compound 6i:  The crude product was purified by silica gel flash column 
chromatography (3:7 hexanes: ethyl acetate, Rf= 0.5) to afford 6i as a clear oil (60% 
yield): 1H NMR (400 MHz, CDCl3) δ 6.46 (s, 1 H), 4.29 (d, 1 H, J= 9.1 Hz), 4.18 (d, 1 
H, J= 9.1 Hz), 2.61 (m, 1 H), 1.59-1.74 (m, 7 H), 1.34 (s, 9 H), 1.05-1.24(m, 9 H), 
0.89 (m, 1 H); 13C NMR (100 MHz, CDCl3) δ 174.04, 172.72, 80.48, 73.45, 50.95, 
44.91, 28.97, 28.59, 27.42, 26.52, 26.51, 26.47, 26.13, 20.13, 20.02; IR (CH2Cl2) 
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3377(s), 2931(s), 1732 (w), 1664(s), 1518(s), 1454(s); CIMS (methane) m/z 295 
(M+H), 239, 194. 
Compound 6j: The crude product was purified by silica gel flash column 
chromatography (3:7 hexanes: ethyl acetate, Rf= 0.35) to afford 6j as a clear oil (63% 
yield): 1H NMR (400 MHz, CDCl3) δ 7.26-7.44 (m, 5 H), 6.49 (s, 1 H), 5.01 (d, 1 H, 
J= 9.0 Hz), 4.28 (d, 1 H, J= 9.0 Hz), 2.11 (s, 3 H), 1.30 (s, 9 H); 13C NMR (125 MHz, 
CDCl3) δ 172.23, 166.11, 143.08, 128.73, 127.76, 125.47, 80.48, 76.97, 51.22, 28.81, 
14.42; IR (CH2Cl2) 3381(m), 3055(s), 2985(s), 1676(s, br), 1518(s); CIMS (methane) 
m/z 261 (M+H), 205, 161. 
Compound 6k: The crude product was purified by silica gel flash column 
chromatography (3:7 hexanes: ethyl acetate, Rf= 0.1) to afford 6k as a clear oil (70% 
yield): 1H NMR (400 MHz, CDCl3) δ 6.46 (s, 1 H), 4.45 (d, 1 H, J= 9.1 Hz), 4.02 (d, 1 
H, J= 9.1 Hz), 2.01 (s, 3 H), 1.43 (s, 3 H), 1.09-1.35 (s, 9 H); 13C NMR (100 MHz, 
CDCl3) δ 173.90, 165.69, 76.41, 74.34, 50.64, 28.57, 26.48, 14.13; IR (CH2Cl2) 
3383(s), 2976(s), 1745(w), 1668(s), 1518(s), 1267(s); CIMS (methane) m/z 199 
(M+H), 171, 143. 
Compound 6l:  The crude product was purified by silica gel flash column 
chromatography (3:7 hexanes: ethyl acetate, Rf= 0.1) to afford 6l as a clear oil (82% 
yield): 1H NMR (400 MHz, CDCl3) δ 7.98-8.12 (m, 2 H), 7.41-7.54 (m, 3 H), 7.36 (s, 
1 H), 4.70 (d, 1 H, J= 9.1 Hz), 4.27 (d, 1 H, J= 9.1 Hz), 4.21 (dd, 2 H, J= 6.9, 4.2 Hz), 
4.05 (ddd, 2 H, J= 14.1, 10.0, 5.6 Hz), 1.62 (s, 3 H), 1.26 (t, 3 H, J= 7.16 Hz); 13C 
NMR (100 MHz, CDCl3) δ 175.44, 169.67, 165.09, 132.18, 130.28, 128.71, 128.65, 
128.60, 127.25, 76.68, 74.73, 61.66, 41.29, 26.56, 14.30; IR (CH2Cl2) 3400(m), 
3055(s), 2986(s), 1745(s), 1680(s), 1520(s), 1265(s); CIMS (methane) m/z 291 (M+H), 
245, 160. 
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Compound 6m: The crude product was purified by silica gel flash column 
chromatography (3:7 hexanes: ethyl acetate, Rf= 0.5) to afford 6m as a white solid 
(58% yield): 1H NMR (300 MHz, CDCl3) δ11.44 (s, 1 H), 6.90-7.71 (m, 4 H), 6.24 (s, 
1 H), 4.65 (d, 1 H, J= 8.8 Hz), 4.22 (d, 1 H, J= 8.8 Hz), 1.59 (s, 3 H), 1.35 (s, 9 H); 
13C NMR (100 MHz, CDCl3) δ 173.10, 166.24, 159.89, 134.38, 128.66, 119.39, 
117.08, 110.48, 76.14, 74.61, 51.32, 28.83, 26.92; IR (CH2Cl2) 3408(m), 3055(s), 
2982(s), 1672(s), 1639(s), 1514(s); CIMS (methane) m/z 277 (M+H), 249, 176. 
Compound 6n:  The crude product was purified by silica gel flash column 
chromatography (3:7 hexanes: ethyl acetate, Rf= 0.2) to afford 6n as a clear oil (63% 
yield): 1H NMR (400 MHz, CDCl3) δ11.37 (s, 1 H), 6.89-7.69 (m, 5 H), 4.70 (d, 1 H, 
J= 8.8 Hz), 4.26 (d, 1 H, J= 8.8 Hz), 4.21(dd, 2 H, J= 14.4, 7.5 Hz),4.03 (ddd, 2 H, J= 
13.4, 18.4, 5.7 Hz), 1.66 (s, 3 H), 1.27 (t, 3 H, J= 7.2 Hz); 13C NMR (125 MHz, 
CDCl3) δ 174.32, 169.44, 166.78, 159.96, 134.49, 128.69, 119.37, 117.15, 110.29, 
76.04, 74.35, 61.84, 41.35, 26.63, 14.30; IR (CH2Cl2) 3423(m), 3055(s, br), 2985(s, 
br), 1745(s), 1680(s), 1639(s), 1518(s); CIMS(methane) m/z 307 (M+H), 176, 86. 
Four-component condensation of ketomesylates using a primary amine. 
Synthesis of aminoester 9a:  To a solution of ketomesylate 4a (0.2 mmol) in 
anhydrous 2,2,2-trifluoroethanol (0.5 mL) at 0 °C was added benzylamine (0.8 mmol) 
by syringe dropwise. The reaction mixture was stirred for 10 min at 0 °C, then acetic 
acid (0.4 mmol) and cyclohexyl isocyanide (0.22 mmol) were added via syringe with 
stirring. The reaction mixture was warmed to rt and stirred for 18 h. The solvent was 
evaporated in vacuo to give an oil, which was purified by silica gel flash column 
chromatography (3:7 hexanes: ethyl acetate, Rf= 0.3) to afford 9a as a white solid (57 
mg, 71%): mp 107-109 °C; 1H NMR (400 MHz, CDCl3) δ 7.14-7.40 (m, 10 H), 4.45-
4.53 (dd, 2 H, J= 18.6, 11.6 Hz), 3.83 (m, 1 H), 3.75 (d, 1 H, J= 12.4 Hz), 3.61 (d, 1 H, 
J= 12.4 Hz), 2.65 (m, 2 H), 2.07 (s, 3 H), 1.82-2.00 (m, 3 H), 1.60-1.73 (m, 4 H), 1.33-
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1.44 (m, 2 H), 1.14-1.24 (m, 3 H); 13C NMR (100 MHz, CDCl3) δ 171.38, 170.72, 
141.56, 139.80, 128.88, 128.65, 128.44, 128.21, 127.62, 126.23, 64.10, 63.97, 47.94, 
47.12, 36.74, 33.45, 33.27, 30.11, 25.65, 24.96, 24.94, 21.08; IR (CH2Cl2) 3350(s), 
2932(s), 1740(s), 1665(s), 1516(s), 1452(s), 1379(s); CIMS (methane) m/z 405 (M+H), 
363, 296.  
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3.1  Introduction 
Multicomponent reactions have attracted the attention and interest of synthetic 
chemists as efficient processes for the assembly of densely functionalized structures. 
MCRs are of special interest in making compounds that exhibit pharmacological 
activity.1 As part of our laboratory’s effort to expand the repertoire of useful MCRs, 
we have investigated the utility of functionalized carbonyl compounds such as acyl 
cyanides2 and acyltetrazoles3 in isonitrile-based multicomponent condensations, 
whose scope has traditionally been limited to simple aldehydes and ketones.4 Here, we 
report a versatile, 4-component condensation of readily available α-diazoketones with 
(two) carboxylic acids and isonitriles to afford a new family of structurally diverse, 
substituted di-O-acylglyceramides 5 (Scheme 3.1). 
 
 
 
 1
R3CO2H CNR4R2CO2H
Cu(acac)2
R1 CH2OCOR3
OCOR2
O NHR4
R1
O
N2
2 3 4 5
Scheme 3.1 Synthesis of Substituted Di-O-acylglyceramides 5 
 
By suitable manipulation of the glyceramide framework in 5, the method can 
be used to create new families of synthetic amphiphilic compounds having potential 
applications as surfactantactive compounds and as carriers for drug encapsulation and 
delivery. 
Simple α-diazoketones proved refractory to the standard conditions of the 
Passerini or Ugi condensations, even when heated to 60–70 °C. However, α-
diazoketones and sulfonic acids spontaneously formed β-ketosulfonates, a family of 
reactive carbonyls that were recently utilized in a new Ugi-based approach to 
substituted 2-oxazolines.5
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3.2  Results and Discussion 
We therefore investigated two-stage, one-pot MCRs of the representative 
diazoketone 1a (Scheme 3.2) triggered by an initial metal-catalyzed insertion into a 
typical carboxylic acid (e.g., HOAc),6,7 followed by an in situ Passerini condensation 
as shown. With Rh2(OAc)4 as catalyst, complex product mixtures were formed from 
which only minor quantities of the initial insertion product 1-acetoxy-4-phenyl-2-
butanone 6a could be isolated. However, using Cu(acac)2 (10 mol %),7 the desired di-
O-acylglyceramide 5a was obtained in 68% yield, along with 6a (26%). 
 
O
OAc
1a
O
N2
Cu(acac)2
AcOH
t-BuNC
AcOH
CH2OAc
OAc
O NHt -Bu
5a
6a
 
 
 
 
 
 
Scheme 3.2 Synthesis of Substituted Di-O-acylglyceramides 5a 
 
Optimization of this 4-component reaction led to several interesting findings. 
To begin with, Shinada et al. used relatively large quantities of Cu(acac)2 (10 mol %) 
for the initial diazoketone insertion reaction, raising the concern that copper 
complexation of the isonitrile component might cause a sequestering effect that would 
interfere with the subsequent Passerini condensation leading to 5. To investigate this 
question, a pure sample of 1-acetoxy-4-phenyl- 2-butanone 6a was subjected to the 
Passerini reaction leading to 5a with and without Cu(acac)2 (5 mol %), and the 
progress of the condensation was monitored by following disappearance of the 
ketoacetate, as shown in Figure 3.1. 
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Figure 3.1 Effects of Cu(acac)2 on the Formation of 5a 
 
As the data in Figure 3.1 illustrate, Cu(acac)2 exerted a mild rate retarding 
effect on the formation of 5a. A similar effect was also noted in Passerini reactions of 
the parent ketone, 4-phenyl-2-butanone, which suggested that complexation by 
Cu(acac)2 depleted the reaction medium of the key of the isonitrile reactant. Besides 
explaining the modest yield of 5a, isonitrile sequestration by copper also accounted for 
the recovery of significant quantities of unreacted ketoacetate 6a. 
One successful solution to the problem involved using excess isonitrile. 
However, to optimize the synthetic efficiency of the process we investigated whether 
lower catalyst loads might also improve the yields of 5. Dropwise addition of 
diazoketone 1a (1.3 equiv) into a toluene solution (60 °C, 30 min) of acetic acid and 
1.0 mol % of Cu(acac)2 followed by in situ Passerini condensation afforded 5a in 94% 
yield. Upon further experimentation, we observed that the diazoketone insertion 
reaction could be achieved equally well in most cases without any metal catalyst, 
although the somewhat higher temperatures required (100–110 °C) led us to favor the 
use of 1 mol % Cu(acac)2 in most circumstances. 
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Table 3.1 summarizes the scope and versatility of the new four component 
synthesis of di-O-acylglyceric acid diamides depicted in Scheme 3.1, which has been 
successfully implemented as a one-pot process. 
 
Table 3.1 Cu(acac)2-Catalyzed 4-Component Condensations of R1COCHN2, R2CO2H, 
R3NC, and R4CO2H Leading to 5 
 
1 R1= 2 R2= 3 R3= 4 R4= Product 
Yield (%) 
Ph(CH2)2 1a CH3 t-Bu CH3 5a (94) 
1a CH3 t-Bu (CH3)2CH 5b (90) 
1a Ph EtO2CCH2 C7H15 5c (72) 
C7H15 1b (CH3)2CH t-Bu CbzNHCH2 5d (70) 
1b Ph cyclo-C6H11 CH3 5e (80) 
cyclo-C6H11 1c C7H15 n-Bu CH3 5f (70) 
1c NCCH2 EtO2CCH2 Ph 5g (76) 
CH3 1d (CH3)2CH n-Bu CbzNHCH2 5h (71) 
1d H(CH2OCH2)3 t-Bu C7H15 5i (58) 
 
The initial insertion reactions were monitored by N2 evolution and usually 
required heating for 30–60 min at 60–90 °C. In reactions using diazoketones 1a–c, 1.3 
equiv of diazoketone was used, whereas insertions using diazoacetone 1d were 
optimally achieved using 1.8 equiv of diazoketone. The scope of the new four-
component condensation appears to be limited to aliphatic diazoketones. In the case of 
benzoyldiazomethane, the initial insertion was successful, but the α-acyloxyketone 
failed to undergo the subsequent Passerini reaction. 
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The product glyceramides 5 were formed as racemic mixtures. With respect to 
controlling the new stereogenic center formed in the second step of the MCR, we were 
intrigued by a recent paper by Andreana et al., reporting that certain a-substituted 
aldehydes capable of bidentate binding underwent enantioselective Passerini reactions 
using an indan (pybox) Cu(II) Lewis acid complex.8 Using the synthesis of 5 h as a 
test case, diazoketone 1d was reacted with isobutyric acid in the absence of Cu(acac)2 
to form the corresponding acyloxypropanone. The subsequent Passerini reaction was 
conducted in the presence of indan (pybox) Cu(II) catalyst (20 mol %) following the 
protocol of Andreana et al. and produced 5 h with no measurable enantiomeric excess. 
3.3  Conclusion 
The new MCR represents a more selective and efficient alternative to the 
stepwise introduction of carboxylic ester groups into the vic-diol backbone of 
glyceramides, since it avoids the potential for ester interchange by competing O,O-
acyl transfer side reactions. As one illustration of its utility, we describe the synthesis 
of a ‘facially amphiphilic’9 diester 5i containing one lipophilic and one hydrophilic 
side chain, each derived from a carboxylic acid. 
3.4 Experimental Procedures 
1H NMR and 13C NMR were taken on a Varian Mercury-300,Varian Inova-400 
or Varian Inova-500 spectrometer as indicated using CDCl3 with 0.05% v/v TMS as 
solvent. Spectra were recorded in δ (ppm) and were referenced to residual TMS (0.00 
ppm for 1H NMR) and CDCl3 (77.23 ppm for 13C NMR). IR spectra were obtained on 
a Thermo Nicolet Avatar 370 DTGS spectrometer and were recorded in wavenumbers 
(cm-1). Chemicals were obtained from Aldrich, Fluka, Fisher, Mallinckrodt and used 
as received unless specified. In reactions leading to diastereomers, spectroscopic data 
were reported for mixtures, unless specified otherwise. 
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Representative experimental procedure for diester 5b: A mixture of acetic acid 
(57 µL, 1.0 mmol) and Cu(acac)2 (2.6 mg, 0.01 mmol, 1 mol %) in toluene (2 mL) in a 
10 mL round bottomed flask was heated to 60 °C for 10 min under nitrogen. To it was 
added dropwise a solution of diazoketone 1a (226 mg, 1.3 mmol, 1.3 equiv) in toluene 
(2 mL). Once gas evolution was judged complete, the reaction mixture was stirred for 
an additional 5 min, then cooled and concentrated in vacuo. The oily residue was 
blanketed in nitrogen, then treated with iso-butyric acid (140 µL, 1.5 mmol, 1.5 equiv) 
and t-BuNC (170 µL, 1.5 mmol, 1.5 equiv). The resulting reaction mixture was stirred 
at rt under N2 for 20 h. The product was purified by flash column chromatography (1:1 
EtOAc/hexanes, Rf = 0.3) to afford 5b (338 mg, 90%) as a pale yellow oil. 
Compound 5b: The crude product obtained was purified by silica gel flash column 
chromatography (1:1 hexanes: ethyl acetate, Rf= 0.4) to afford 5b as a yellow oil (279 
mg, 77%): 1H NMR (300 MHz, CDCl3) δ  7.12-7.28 (m, 5 H), 6.39 (s, 1 H), 4.90 (d, 1 
H, J= 11.5 Hz), 4.42 (d, 1 H, J= 11.5 Hz), 2.46-2.61 (m, 4 H), 2.28 (m, 1 H), 2.02 (s, 3 
H), 1.41 (s, 9 H), 1.20 (dd, 6 H, J= 7.0, 2.5Hz); 13C NMR (125 MHz, CDCl3) δ 174.53, 
170.15, 168.63, 140.86, 128.71, 128.67, 126.40, 85.74, 64.98, 51.64, 35.05, 33.35, 
29.72, 28.93, 20.86, 19.35, 19.21; IR (neat) 3438(s), 2970(s), 1745(s), 1691(s); CIMS 
(methane) m/z: 378.3 (M+H), 308.2, 209.2. 
Compound 5c: The crude product obtained was purified by silica gel flash column 
chromatography (3:7 hexanes: ethyl acetate, Rf= 0.3) to afford 5c as a pale yellow oil 
(347 mg, 64%): 1H NMR (300 MHz, CDCl3) δ 7.97 (d, 2 H), 7.12-7.58 (m, 8 H), 5.24 
(d, 1 H, J= 11.7 Hz), 4.64 (d, 1 H, J= 11.7 Hz), 4.24 (q, 2 H, J= 7.2 Hz), 4.10 (t, 2 H, 
J= 6.3 Hz), 2.61 (m, 2 H), 2.22-2.46 (m, 4 H), 1.61 (m, 2 H), 1.10-1.40 (m, 13 H), 0.88 
(t, 3 H, J= 5.0 Hz ); 13C NMR (125 MHz, CDCl3) δ 171.62, 170.22, 169.72, 165.72, 
140.65, 133.36, 129.89, 129.81, 128.72, 128.62, 128.58, 126.33, 85.96, 65.27, 61.92, 
41.62, 35.14, 34.09, 33.49, 31.83, 31.76, 29.72, 29.22, 29.11, 25.13, 24.90, 22.79, 
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22.78, 14.35, 14.27, 14.24; IR (neat) 3389(b), 2935(s), 2852(s), 1745(s), 1727(s), 
1684(s); CIMS (methane) m/z: 526.3 (M+H), 400.2, 382.2. 
Compound 5d: The crude product obtained was purified by silica gel flash column 
chromatography (3:7 hexanes: ethyl acetate, Rf= 0.3) to afford 5d as a pale yellow oil 
(365 mg, 70%): 1H NMR (300 MHz, CDCl3) δ 7.36 (s, 5 H), 6.31 (s, 1 H), 5.26 (t, 1 H, 
J= 5.0 Hz), 5.13 (s, 1 H), 4.90 (d, 1 H, J= 11.8 Hz), 4.37 (d, 1 H, J= 11.8 Hz), 3.96 (t, 
2 H, J= 6.6 Hz), 2.52 (m, 1 H), 2.19 (m, 1 H), 1.95 (m, 1 H), 1.58 (s, 2 H), 1.37 (s, 9 
H), 1.24 (b, 10 H), 1.13 (dd, 6 H J= 7.0, 2.3 Hz), 0.86 (t, 3 H, 6.3 Hz ); 13C NMR (125 
MHz, CDCl3) δ 176.60, 168.22, 167.72, 156.54, 136.17, 128.80, 128.55, 128.31, 87.53, 
67.48, 64.48, 51.73, 43.70, 34.11, 32.11, 31.87, 29.44, 29.19, 28.82, 22.99, 22.78, 
19.20, 19.11, 14.29; IR (neat) 3422(m), 3339(b). 2961(s), 2927(s), 2857(s), 1735(s), 
1672(s); CIMS (methane) m/z: 521 (M+H), 413, 312. 
Compound 5f: The crude product obtained was purified by silica gel flash column 
chromatography (1:1 hexanes: ethyl acetate, Rf= 0.3) to afford 5f as a clear oil (70%): 
1H NMR (300 MHz, CDCl3) δ 6.28 (t, 1 H, J= 5.0 Hz), 4.96 (d, 1 H, J= 11.5 Hz), 4.69 
(d, 1 H, J= 11.5 Hz), 3.29 (q, 2H, J= 7.2 Hz), 2.26 (t, 3 H), 2.12 (s, 3 H), 1.0-1.80 (m, 
30 H), 0.80-1.00 (m, 6 H); 13C NMR (75 MHz, CDCl3) δ 172.96, 168.85, 87.52, 63.38, 
41.90, 39.24, 34.32, 31.78, 29.15, 29.08, 27.55, 27.32, 26.54, 26.41, 26.18, 25.09, 
22.73, 22.06, 20.21, 14.18, 13.86; CIMS (methane) m/z: 412 (M+H), 370, 352, 268. 
Compound 5g: The crude product obtained was purified by silica gel flash column 
chromatography (1:1 hexanes: ethyl acetate, Rf= 0.4) to afford 5g as a clear oil (337 
mg, 76%): 1H NMR (300 MHz, CDCl3) δ 8.05 (d, 2 H, J= 5.0 Hz), 7.44-7.66 (m, 3 H), 
6.99 (t, 1 H, J= 5.0 Hz), 5.26 (d, 1 H, J= 11.5 Hz), 5.00 (d, 1 H, J= 11.5 Hz), 4.24 (q, 
2H, J= 7.2 Hz), 4.12 (dd, 2H, J= 3.5, 1.5 Hz), 3.40 (s, 2 H), 2.46 (m, 1 H), 1.75-1.88 
(m, 4 H), 1.10-1.40 (m, 9 H); 13C NMR (125 MHz, CDCl3) δ 169.97, 169.34, 165.11, 
162.50, 134.18, 130.25, 130.09, 129.27, 113.12, 88.23, 66.17, 62.20, 42.39, 41.82, 
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27.95, 27.59, 26.74, 26.61, 26.37, 25.02, 14.59; IR (neat) 3426(s), 2930(s), 2854(s), 
1757(s), 1726(s), 1683(s); CIMS (methane) m/z: 445 (M+H), 360, 323. 
Compound 5h: The crude product obtained was purified by silica gel flash column 
chromatography (1:1 hexanes: ethyl acetate, Rf= 0.3) to afford 5h as a pale yellow oil 
(71%): 1H NMR (400 MHz, CDCl3) δ 7.13-7.40 (m, 5 H), 6.54 (s, 1 H), 5.30 (s, 1 H), 
5.13 (q, 2 H), 4.71 (dd, 1H), 4.43 (dd, 1H), 3.93 (m, 2 H), 3.26 (m, 2 H), 2.53 (m, 1 H), 
1.68 (s, 3 H), 1.51 (m, 2 H), 1.35 (m, 2 H), 1.14 (d, 6 H), 0.93 (t, 3 H); 13C NMR (125 
MHz, CDCl3) δ 176.55, 169.75, 168.10, 156.91, 136.11, 128.81, 128.58, 128.25, 83.85, 
67.52, 65.48, 43.83, 39.60, 34.06, 31.67, 20.32, 20.23, 19.13, 19.06, 13.96; IR (neat) 
3336(s), 2953(s), 2927(s), 1738(s), 1659(s), 1536(s); CIMS (methane) m/z: 437 
(M+H), 393, 349. 
Compound 5i: The crude product obtained was purified by silica gel flash column 
chromatography (1:1 hexanes: ethyl acetate, Rf= 0.2) to afford 5i as a pale yellow oil 
(58%): 1H NMR (300 MHz, CDCl3) δ 6.07 (s, 1 H), 4.80 (dd, 1H), 4.48 (dd, 1H), 4.13 
(d, 2 H), 3.55-3.75 (m, 8 H), 3.38 (s, 3 H), 2.34 (t, 2 H), 1.64 (s, 3 H), 1.5-1.7 (s, 4 H), 
1.36 (s, 9 H), 1.20-1.40 (s, 8 H), 0.89 (t, 3 H); 13C NMR (125 MHz, CDCl3) δ 171.72, 
169.82, 169.32, 82.27, 72.05, 71.12, 70.81, 70.72, 68.48, 65.92, 59.23, 51.46, 35.18, 
31.82, 29.17, 29.13, 28.75, 25.09, 22.78, 20.00, 14.26; IR (neat) 3512(s), 3445(s), 
2957(s), 2927(s), 2867(s), 1745(s), 1678(s); CIMS (methane) m/z: 462 (M+H), 336, 
318, 284. 
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4.1 Introduction 
The discovery in 1850 that α-amino acids could be prepared in one step from 
simple reactants using the Strecker reaction, the first reported example of a 
multicomponent reaction, launched a period of intensive synthetic chemical 
development that remains active today. Generally defined as one-pot processes that 
produce a desired target from the combination of three or more reactants,1 MCRs can 
create simple and convergent paths to structurally complex products in atom-
economical2 fashion. With the advent of combinatorial chemistry and its widespread 
adoption by the pharmaceutical industry, MCR chemistry experienced a renaissance of 
interest in the past two decades, triggered initially by the demand for screening 
libraries in drug discovery programs, and stimulated more recently by efforts to 
assemble natural product-like scaffolds exhibiting specific pharmacological profiles. 
To date, MCR reactions based on the chemistry of isonitriles have been 
particularly widely used in these endeavors, despite the well-known drawbacks to 
using this family of compounds. Besides their unpleasant olefactory properties, 
isonitriles have generally been limited in their commercial availability and have 
limited shelf stability. In recent years, however, versatile new syntheses of isonitriles 
have been developed,3 including routes to convertible isonitriles possessing pleasant 
aromas,4 that promise to expand the repertoire of known MCRs.  
The Passerini and Ugi reactions, which represent the two most widely 
employed isonitrile-based MCRs, also need simple carbonyl compounds as integral 
reactants. As part of our efforts to synthesize new molecular frameworks by using the 
“single reactant replacement” (SRR) strategy to evolve existing MCRs, we have 
investigated aldehydes and ketone surrogates that combine carbonyl electrophilic 
properties with additional embedded reactivity elements. For example, we recently 
discovered that replacing simple carbonyl compounds in the Passerini reaction with 
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acyl cyanides made it possible to redirect the outcome to afford β-aminoacid diamides 
instead of the conventional α-acyloxyamides,5 and further empowered the assembly of 
densely functionalized oxazoles and tetrazoles.6  
We also investigated the use of α-diazoketones in isonitrile based MCRs, 
finding them resistant to Passerini and Ugi reactions. However, by exploiting the 
reactivity of diazocarbonyls to Bronsted acids or transition metal catalysis, we recently 
achieved successful one-pot, four-component condensations that furnished substituted 
oxazolines via α-sulfonyloxyketones7 as well as substituted di-O-acylglyceramides 
from α-acyloxyketones.8 Following those communications, we now report a full 
account of our studies using α-substituted ketones as surrogates for simple carbonyl 
compounds in the Ugi and Passerini reactions.  
The rationale for this study was to investigate SRR outcomes when reactive 
functionality was embedded at the α-position of the ketone. While several reactive α-
substituents were of potential interest (sulfonyloxy, acyloxy, azido, halo, hydroxyl and 
sulfonyl), almost nothing was known about their MCR chemistry, let alone relative 
reactivities. Prior to our own oxazoline-forming synthesis, there were no reports of 
Passerini or Ugi condensations on α-mesyloxy- or tosyloxyketones. Likewise, no 
examples of MCRs of α-azido-, α-hydroxy-, or α-sulfonylketones have been 
described in the literature. Enantioselective, copper-catalyzed Passerini reactions of 
alkoxysubstituted aldehydes have recently been described,9 but no examples of the 
corresponding alkoxyketones were included. α-chloroketones have been reported to 
undergo the Passerini condensation, forming chloro-substituted acyloxyamides, which 
after subsequent base treatment were transformed into the corresponding acyloxy-β-
lactams.10  
It occurred to us that any pronounced rate differences between these various 
substituted ketones might make it possible to achieve selectivity when using mixtures 
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of two or more carbonyl compounds, thus broadening the opportunities for 
incorporating novel functionality in MCRs. Anchimeric effects involving the 
neighboring α- substituent might also be exploited to produce new molecular 
frameworks. Here we report the relative rates of condensation of a representative 
series of α-substituted ketones in the Passerini condensation. That kinetic study 
provides useful new insights into the relative reactivity of each family and suggests 
additional directions for new work. 
4.2 Results and Discussion 
Preparation of Substrates. The starting material for all α-substituted ketones 
was the corresponding α-diazoketone 1 (Scheme 4.1), which could be conveniently 
prepared by reaction of the cognate acid chloride with diazomethane. Initially, the 
readily available 1-diazo-4-phenyl-2-butanone 1a (prepared from hydrocinnamoyl 
chloride) was used to synthesize a representative example of each family of 
substituted ketones. Reaction of 1a with methanesulfonic acid or toluenesulfonic acid 
furnished the mesyloxy and tosyloxyketones 2a and 3a, respectively.11 The 
corresponding acyloxyketone 4a (R2 = CH3) was prepared from 1a by Cu(acac)2-
catalyzed reaction with acetic acid.12 Chloroketone 5a was obtained from 1a by 
reaction with HCl in ether.13  
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Scheme 4.1 Preparation of Substrates 
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Azidoketones 6 and arylsulfonylketones 7 were both prepared according to 
literature methods from the corresponding chloroketones 5. Thus, azidoketone 6a 
arose from the reaction of 5a with NaN3 in DMF.14 The synthesis of α-sulfonylketone 
7a (Ar = Ph) was achieved by reaction of 5a with thiophenol and NaOH in the 
presence of oxone.15 A sample of the parent unsubstituted ketone, benzylacetone 8a, 
was obtained commercially and used as a control compound for the kinetic study. 
Relative Rate Study of α-Substituted Ketones in the Passerini Reaction. 
Compounds 2a and 4a-8a were subjected to a representative Passerini condensation 
with acetic acid and t-butyl isonitrile (1.0 equiv each) under neat conditions at rt. 
Aliquots of each reaction mixture were removed for NMR analysis, and the progress 
of the reaction was monitored by the relative amounts of starting ketone (as judged by 
integration of the singlet resonance for the α-methylene carbon) and the 
Passerini product (as measured by the AB-quartet for the same methylene group). The 
results are tabulated in Figure 4.1. 
 
 
 
 
 
 
 
 
 
Figure 4.1 Relative Rates of a Representative Passerini Condensation of  
α-Substituted Ketones. 
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As the data indicate, each of the α-substituted ketones underwent Passerini 
condensation more rapidly than the parent carbonyl compound 8a. Mesyloxyketone 2a 
was the most reactive carbonyl compound tested. Although tosylate 3a was not 
included in the rate study, independent side-by-side comparisons of 2a and 3a in other 
Passerini and Ugi condensations (vide infra) established that 3a displayed comparable 
reactivity in isonitrile-based MCRs. Chloroketone 5a and azidoketone 6a showed 
similar rate profiles, and were somewhat more reactive than acyloxyketone 4a. 
Sulfonylketone 7a was the least reactive of the substituted ketones tested, undergoing 
Passerini condensation only slightly faster than 8a. The kinetic data in Figure 4.1 were 
consistent with the expected enhancement of carbonyl electrophilicity caused by 
electronegative substituents, as judged by known Pauling atom or group 
electronegativity values for each of the substituents tested.16 Results with compounds 
2a, 5a, and 6a suggested that selective Passerini condensations on these substances 
might be possible in the presence of a sulfonyl-substituted or unsubstituted ketone. As 
a preliminary test of this hypothesis, a 1:1 mixture of chloroacetone 5b (R1 = CH3) and 
phenylsulfonylacetone 7b  (R1 = CH3) were reacted with 1 equiv each of acetic acid 
and t-butyl isonitrile (24 h, rt) to afford an 8:1 ratio of products from 5b and 7b, 
respectively. 
Isonitrile-Based MCRs of Substituted Ketones. Mesyloxy and 
tosyloxyketones 2 and 3 proved to be very good carbonyl components in the Passerini 
reaction, typically forming the expected products 9 and 10, respectively, in high yields 
(Scheme 4.2). 
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Scheme 4.2 Passerini Reaction of Mesyloxy- and Tosyloxyketones 
 
The results of a representative sampling of condensations using various 
carboxylic acids and isonitriles (1.1 equiv each) are summarized in Table 4.1. 
Condensations of 2 and 3 were generally completed in 12-18 h and successfully 
furnished the expected products in very good to excellent yields. Products 9 and 10 
were readily purified by flash column chromatography. Furthermore, the possibility of 
directly converting the parent α-diazoketone to mesylate 9a was realized in a simple 
one-pot process by reacting a CH2Cl2 solution of diazoketone 1a with methanesulfonic 
acid (1.1 equiv, 10 min, 0 °C). After addition of NaOAc (0.5 equiv) to neutralize 
residual acid, the solution was treated with acetic acid and cyclohexyl isonitrile (rt 24 
h) to afford 9a in 86% yield. 
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Table 4.1 Passerini Reactions of Mesyloxy- and Tosyloxyketones 
mesylate/tosylate 
R1= 
R2CO2H 
R2= 
R3NC 
R3= 
Product 
(Yield) 
2a  Ph(CH2)2 CH3 t-Bu 9a (88%) 
2a Ph cycle-C6H11 9b (82%) 
2a CH3 cycle-C6H11 9c (80%) 
2b  n-C7H15 CH3 cycle-C6H11 9d (91%)  
2c  cycle-C6H11 Ph n-Bu 9e (80%) 
2d  Ph CH3 cycle-C6H11 9f (18%) 
3a Ph(CH2)2 Ph t-Bu 10a (99%)  
3a Ph cycle-C6H11 10b (97%) 
3b n-C5H11 CH3 cycle-C6H11 10c (97%) 
3b Ph cycle-C6H11 10d (99%) 
3c  cycle-C6H11 CH3 t-Bu 10e (80%)   
3d  Ph Ph cycle-C6H11 10f (28%)  
 
With their reactive sulfonate leaving groups, sulfonates 9 and 10 were also 
well-suited precursors for the synthesis of substituted β-lactams 11 (Scheme 4.3) 
following a procedure developed for cyclizations of the corresponding chloro 
compounds.10 
 
 OCOR2
 
 
Scheme 4.3 Synthesis of Acyloxy-β-lactams 11 from  
Mesyloxy- and Tosyloxyketones 
9
NaH R1
O
N
R3
NaH
DMF/CH2Cl2
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11
DMF/CH2Cl2
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Table 4.2 summarizes results obtained in our laboratory using this approach to 
substituted β-lactams from representative sulfonates 9 and 10. While the yields of 11a-
e were generally comparable whether from the mesylate or tosylate precursor, the 
cyclization was noticeably more rapid in the case of mesylate 9c. 
 
Table 4.2 Synthesis of Acyloxy-β-lactams 11 from Sulfonates 9 and 10 
 sulfonate product (yield)  
 9c 11a (62%)  
 10a 11b (46%)  
 10b 11c (59%)  
 10c 11d (64%)  
 10d 11e (56%)  
 
We also investigated Ugi reactions of sulfonyloxyketones 2 and 3. When using 
ammonia as the amine, the MCR led to a novel 4-component synthesis of substituted 
2-oxazolines 13 (Scheme 4.4) by way of the intermediate diamides 12.7 Apparently 
the formation of imines derived from 2 or 3 was faster than ammonolysis of the 
mesylate or tosylate group, thus triggering the desired Ugi reaction to form 12. The 
fact that 12 cyclized spontaneously to 13 during the reaction finds precedent in the 
known biosynthesis of peptide-based oxazolines17 by cyclization of activated N-
acylserine derivatives.18 
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Scheme 4.4 Synthesis of Oxazoline 13 from Sulfonates 9 and 10 
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Initial studies of this interesting transformation with 2a as a representative 
mesyloxyketone utilized methanol as solvent, a common medium for Ugi 
condensations, and also afforded significant quantities of the corresponding Passerini 
product 9. This byproduct could be effectively suppressed by replacing methanol with 
2,2,2-trifluoroethanol, a solvent that was recently reported to improve Ugi reactions 
involving ammonia as the amine component.19 Overall, the new oxazoline synthesis, 
for which full experimental details on 14 examples have been reported,7 
accommodated a broad range of sulfonyloxyketones, isonitriles and carboxylic acids. 
Our initial communication noted that when NH3 was replaced with 
benzylamine, the MCR of 2a with acetic acid and cyclohexyl isonitrile afforded 
aminoester 15a (Scheme 4.5) as the exclusive product. Particularly characteristic was 
the strong ester carbonyl band (1740 cm-1) in the IR spectrum of 15a. 
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Scheme 4.5 Ugi Reactions of Mesyloxyketones 2 with Primary Amines 
 
A mechanism of formation of 15a paralleling that of 13 could be envisioned in 
which hydrolysis of the oxazolinium intermediate 14a led to the observed product. 
Interestingly, 15a did not undergo 1,2-acyl shift, leading to the corresponding 
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amidoalcohol 16a. Further confirmation of the structure of 15a was obtained by single 
crystal X-ray diffraction analysis. 
Structures such as 16a embody the hydroxyethylene or hydroxyethyl structural 
unit found in transition state isosteres such as statine or norstatine, which have been 
developed as inhibitors of retroviral proteases.20 Given their potential biomedical 
significance, we have investigated this MCR further. As indicated in Table 4.3, several 
other primary amines and mesyloxyketones formed the corresponding amidoesters 15. 
In each case, only the amidoester isomer 15 (and none of the diamide 16) was detected. 
 
Table 4.3 Ugi Reactions of Mesyloxyketones 2 with Primary Amines 
mesylate 2 
R1= 
R2CO2H 
R2= 
R3NH2
R3= 
R4NC 
R4= 
Product 
(Yield) 
2a  Ph(CH2)2 CH3 Bn cycle-C6H11 15a (71%) 
2a i-Pr allyl cycle-C6H11 15b (66%) 
2b  n-C7H15 Ph Bn t-Bu 15c (67%)  
2b i-Pr allyl cycle-C6H11 15d (61%) 
2b CH3 i-Pr cycle-C6H11 9e (70%) 
2c  cycle-C6H11 i-Pr n-Bu t-Bu 15e (39%) 
2d  CH3 CH3 Bn t-Bu 15f (74%) 
 
To determine whether the products observed in each case were formed under 
kinetic control, aminoester 15a was subjected to basic (DBU-CH3CN, Et3N, NaH-
DMF) equilibration conditions. However, no evidence for the formation of diamide 
16a was obtained from these experiments. 
The complementary equilibration experiment required an authentic sample of 
16a, which we attempted to synthesize from acetoxyketone 4a in two steps using the 
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Ugi reaction as shown below (Scheme 4.6). Little is known about Ugi condensations 
of such acyloxyketones. In fact, reaction of 4a with ammonia, acetic acid, and 
cyclohexyl isonitrile returned mostly starting ketoacetate 4a, along with the 
corresponding Passerini product (not shown) in 14% yield. However, replacing 
ammonia with benzylamine did afford the desired MCR product 17a in 67% yield. 
 
Bn Bn
 
 
 
Scheme 4.6 Hydrolysis of the Ugi Product 17a 
 
Treatment of 17a with NH3-CH3OH was expected to furnish 16a by 
methanolysis of the more reactive acetate ester. Instead, two products were formed: 
aminoester 15a (20%) and aminoalcohol 18a (60% yield). Unfortunately, none of the 
hoped for amidoalcohol 16a could be detected by IR. 
In an alternative approach (Scheme 4.7), the known21 hydroxyketone 19 was 
subjected to the Ugi reaction with benzylamine, acetic acid and cyclohexyl isonitrile. 
Instead of the expected amidoalcohol 16a, the sole product of that reaction (56%) was 
aminoester 15a. Taken together, the results depicted in Schemes 6 and 7, while not 
conclusive, were consistent with the rapid conversion of 16a to 15a and its hydrolysis 
product 18a. 
 
 
 
 
Scheme 4.7 Ugi Reaction of β-Hydroxy Ketone 19 
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It became apparent from efforts to prepare 16a that Ugi condensations of 
acyloxyketones 4, while feasible, suffered certain limitations. Therefore, we decided 
to study the reactivity of acyloxyketones in the corresponding Passerini reactions. A 
recently published preliminary report summarized our findings in this area.8 Since 
acyloxyketones of general structure 4 were easily prepared by copper-catalyzed 
insertion of diazoketone 1 into a carboxylic acid,22 we were able to develop a versatile 
one-pot 4-component condensation in two stages leading to a new family of 
structurally diverse di-O-acylglyceric acid amides 20 (Scheme 4.8). 
 
 
 
 
 
Scheme 4.8 Four-Component Condensations of Diazoketone 1 Leading to  
Di-O-acylglyceric Acid Amides 20 
 
The initial insertion stage required heating of 1 with R2CO2H (30-60 min, 
toluene, 60-90 °C), usually in the presence of 1.0 mol % Cu(acac)2. Once gas 
evolution ceased, the toluene was removed in vacuo and the crude acyloxyketone 4 
was subjected to a Passerini condensation with R3NC and R4CO2H. Table 4.4 
summarizes the range of new glyceramide diesters thatcould be synthesized using this 
method. 
 
 
 
 
R4CO2H
CNR3R2CO2H
Cu(acac)2
R1 CH2OCOR4
OCOR2
O NHR3
R1
O O
N2
1 4 20
R1
OCOR2
 54
Table 4.4 Four-Component Condensations of Diazoketone 1 Leading to  
Di-O-acylglyceric Acid Amides 20 
 
 
1 R1= 
R2CO2H 
2 R2= 
R3NC 
3 R3= 
R4CO2H 
4 R4= 
Product 
(Yield) 
Ph(CH2)2 1a CH3 t-Bu CH3 20a (94%) 
1a CH3 t-Bu (CH3)2CH 20b (90%)
1a Ph EtO2CCH2 C7H15 20c (72%) 
C7H15 1b (CH3)2CH t-Bu CbzNHCH2 20d (70%)
1b Ph cyclo-C6H11 CH3 20e (80%) 
cyclo-C6H11 1c C7H15 n-Bu CH3 20f (70%) 
1c NCCH2 EtO2CCH2 Ph 20g (76%) 
CH3 1d (CH3)2CH n-Bu CbzNHCH2 20h (71%)
1d H(CH2OCH2)3 t-Bu C7H15 20i (58%) 
 
One advantage of the method over stepwise acylation of the vic-diol moiety in 
glyceramides is that it avoids the potential for ester interchange by competing O,O-
acyl transfer side reactions. Moreover, by using one hydrophobic and one hydrophilic 
carboxylic acid (e.g., 20i), the approach depicted in Scheme 8 can be used to 
synthesize facially amphiphilic glyceramides for potential biomedical use, whether as 
cell wall disrupting agents displaying antifungal activity or as encapsulating agents in 
micellar drug delivery. The method can be adapted to introduce different chain lengths 
in each ester group to fine tune desired hydrophobic/hydrophilic properties. 
The use of α-chloroketones 5 in isonitrile-based multicomponent reactions 
were also of interest in this investigation. Since Passerini reactions of 5 have already 
been described,10 we turned our attention to Ugi 4-component condensations of 
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chloroacetone 5b (R = CH3) as a representative chloroketone using conditions 
optimized for the corresponding mesyloxyketones 2. Thus, reaction of 5b with 
ammonium acetate (4 equiv) and t-butyl isonitrile (1.1 equiv, rt, 24 h) in 
trifluoroethanol solvent afforded the normal Ugi product 21a in very good yield. 
Likewise, condensation of 2b with NH4OAc and cyclohexyl isonitrile also afforded 
the expected Ugi product 21b, along with small quantities of the corresponding 
Passerini product 22, Scheme 4.9. 
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Scheme 4.9 Ugi Reaction of Chloroketone 5b 
 
Using benzylamine instead of ammonia, the Ugi condensation of 5b took a 
different path, forming aminoester 15f (Scheme 4.10) in 74% yield, along with a small 
amount of the corresponding Passerini product (14%, structure not shown). As 
depicted in Scheme 4.10, the formation of aminoester 15f likely proceeded by an 
initial Ugi reaction leading to 23, followed by a rearrangement via 14f similar to that 
invoked for related structures 15a-e (Scheme 4.5). 
 
 
 
 56
 H3C
O
Cl
5b
BnNH3OAC
t-BuNC
H3C CH2OAc
NHBn
O NHt-Bu
15f
H3C CH2Cl
BnN
O NHt-Bu
O
H3C
BnN
O NHt-Bu
O
23 24
 
 
 
 
 
 
 
Scheme 4.10 Ugi Reaction of Chloroketone 5b with Benzylamine 
 
Chloroketone-derived Ugi products like 21a and 21b would be particularly 
useful if they underwent cyclization to the corresponding acylamino-β-lactams 24 
(Scheme 4.9, 4.11), which embody the key structural element of penicillins, 
cephalosporins, and other β-lactam antibiotics at the forefront of modern antimicrobial 
chemotherapy.23 Not surprisingly, however, exposure of 21a to mild base instead 
formed the known17 oxazoline 13a. 
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Scheme 4.11 Cyclization of Ugi Product 21a 
 
We reasoned that replacing the acetamide group in 21a with a phthalimide 
would block the undesired formation of an oxazoline. Moreover, if the Ugi 
condensation of 5b using phthalic acid in combination with ammonia and t-
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butylisonitrile were successful, the initally formed phthalimidic acid 25 (Scheme 4.12) 
might spontaneously dehydrate to the phthalimide 26 either during workup or upon 
standing, thus paving an approach to the desired β-lactam 27. 
 
 
 
 
 
Scheme 4.12 Ugi Condensation of 5b Using Phthalic Acid 
 
After testing the solubility of ammonium phthalate in various solvents, we 
chose methanol as the solvent for the Ugi reaction depicted in Scheme 11. 
Chloroketone 5b was added to a suspension of ammonium phthalate (4 equiv, 0 °C, 10 
min), followed by t-butyl isonitrile (1.1 equiv, rt. 16 h). Extractive workup afforded 
acylaziridine 28 (Scheme 4.13) in 33% yield. However, when the Ugi reaction was 
repeated using the less nucleophilic trifluoroethanol as solvent, only traces of 
phthalimide 26 were detected by mass spectrometry. Instead, the major product was 
hydroxyamide 29, apparently the result of a 2-component Passerini condensation. The 
structure of 29 was confirmed by single crystal X-ray analysis (Figure 4.2). 
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Figure 4.2 ORTEP Diagram of the X-ray Crystal Structure of 29 
 
The relatively rapid Passerini reaction of 6a (Figure 4.1) suggested that such 
azidoketones, although heretofore unstudied in isonitrile-based MCRs, would be good 
substrates for such complexity-generating processes. Furthermore, alkyl azides are 
particularly useful components in the synthesis of triazoles and tetrazoles by copper-
catalyzed cycloadditions with alkynes using “click” chemistry.24 As shown in Scheme 
4.14, representative Ugi condensations of 6a and 6d (R = CH3) with ammonium 
acetate and t-butyl isonitrile afforded the expected diamides 30 and 31 (Scheme 4.14) 
in reasonable yield. 
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Scheme 4.14 Ugi Reaction of Azidoketones 6a, 6d 
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We also investigated isonitrile-based MCRs of α-arylsulfonylketones having 
general structure 7. Unlike other representative α-substituted ketones in this study, 
sulfonylketones (also known as β-ketosulfones) are distinguished by their relatively 
acidic methylene hydrogens and have widespread applications, in the synthesis of 
disubstituted alkynes,25 alkenes,26 allenes,27 and heterocycles.28 Some β-ketosulfones 
function as aromatase inhibitors29 and also exhibit fungicidal activity.30 The Passerini 
condensation of phenylsulfonyl ketone 7a (Scheme 4.15) with acetic acid and t-butyl 
isonitrile (1 equiv each) reported in the kinetic study (Figure 4.1) proceeded smoothly 
(rt, 1 d) to afford the expected product 32a (46% yield) as an inseparable 1:1 mixture 
with 7a, based on NMR analysis. 
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Scheme 4.15 Passerini Reactions with α-Arylsulfonylketones 7 
 
The process seemed to be general, judging from the representative cases shown 
in Table 4.5, in which variations to the arylsulfonyl group and to the carbon 
framework of the ketone were introduced. Unlike 32a, products 32b-f were obtained 
pure after flash chromatography. Interestingly, using 2 equiv of acid and isonitrile 
shortened the overall reaction time, but failed to improve the yield of product. 
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Table 4.5 Passerini Reactions with α-Arylsulfonylketones 7 
 
α-arylsulfonylketones 
7 
R2CO2H 
R2= 
R3NC 
R3= 
product 
(yield) 
7a  R1=Ph(CH2)2, Ar=Ph CH3 t-Bu 32a (46%) 
7b  R1= CH3, Ar=Ph CH3 n-Bu 32b (40%)
7b Ph t-Bu 32c (50%) 
7b (CH3)2CH cyclo-C6H11 32d (69%)
7c  R1= CH3, Ar=p-FC6H4 Ph cyclo-C6H11 32e (40%) 
7c Ph t-Bu 32f (36%) 
 
A representative Ugi condensation using phenylsulfonyl ketone 7b with 
ammonium acetate and t-butyl isonitrile was performed as an initial reactivity test, and 
afforded the expected product 33a (Scheme 4.16, 54%). However, additional 
examples summarized in Table 4.6 defined a narrow scope of reactivity.  
 
 NHAcO
 
 
 
Scheme 4.16 Ugi Reactions with α-Arylsulfonylketones 7 
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Table 4.6 Ugi Reactions with α-Arylsulfonylketones 7 
 
α-arylsulfonylketones 
7 
R2CO2H 
R2= 
R3NH2
R3= 
R4NC 
R4= 
product 
(yield) 
7b  R1= CH3, Ar=Ph CH3 H t-Bu 33a (54%) 
7b Ph H t-Bu 33b (<5%) 
7b CH3 H CH2CO2Et 33c (64%) 
7c  R1= CH3, Ar=p-FC6H4 CH3 H n-Bu 33d (51%) 
 
In entry 2, the low yield obtained of product 33b could not be improved by 
switching the solvent to the more commonly used methanol, and was apparently due 
to the poor solubility of benzoic acid in either solvent. Attempts to use benzylamine 
in place of ammonia produced complex mixtures in which neither the Ugi (expected) 
nor Passerini product could be identified. Generally, the reaction was successful with a 
number of isonitriles including t-butyl or n-butyl isonitrile as well as ethyl 
isocyanoacetate. 
4.3 Conclusion 
In conclusion, we have shown that numerous α-functionalized ketones having 
general structures 2-7 can serve as useful carbonyl components in isonitrile-based 
MCRs, occasionally with unexpected and surprising outcomes. The successful 
application of Passerini and Ugi condensations to families of ketones 2-7 enhances the 
utility of these two powerful name reactions, and adds another dimension to the 
structural complexity that can be achieved using multicomponent reactions. 
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4.4 Experimental Procedures 
Melting points were uncorrected. 1H NMR and 13C NMR were taken on a 
Varian Mercury-300, Varian Inova-400 or Varian Inova-500 spectrometer as indicated 
using CDCl3 with 0.05% v/v TMS as solvent. Spectra were recorded in δ (ppm) and 
were referenced to TMS (0.00 ppm for 1H NMR) and CDCl3 (77.23 ppm for 13C 
NMR). IR spectra were obtained on a Mattson Instruments Galaxy Series FT-IR 
spectrometer and were recorded in wavenumbers (cm-1). Chemicals were obtained 
from Aldrich, Fluka, Fisher, Lancaster, Mallinckrodt, or Novabiochem and used as 
received unless specified. Ether was distilled from sodium/benzophenone. Methanol 
and 2,2,2-trifluoroethanol was distilled from CaH2.  
Representative Procedure for the Passerini Reaction of α-Mesyloxyketones 2. 
Compound 9a: α-mesyloxyketone 2a (48 mg, 0.2 mmol, 1equiv) was added in a 5 mL 
round bottom flask as solid.  It was blanketed in nitrogen, then treated with acetic acid 
(13 µL, 0.22 mmol, 1.1 equiv) and t-butyl isocyanide (25 µL, 0.22 mmol, 1.1 equiv). 
The resulting homogeneous mixture was stirred at rt under N2 for 20 h. The product 
was purified by flash column chromatography ( 3:7 EtOAc/hexanes, Rf=0.2 ) to afford 
9a ( 68 mg, 88%) as a pale yellow oil.  
Representative Procedure for the Synthesis of Acyloxy β-lactams.  
Compound 11a: sodium hydride (80% mineral oil dispension, 9 mg, 0.3 mmol, 1.5 
equiv) was added in a dry 25 mL round bottom flask as solid.  It was washed with 1 
mL pentane twice, then suspended in  4:1 DCM/DMF (3 ml) under nitrogen at 0 °C. 
To it was added 9c solution (82 mg, 0.2 mmol,  in 3 mL 4:1 DCM/DMF ) drop wise . 
The reaction mixture was stirred at rt for 2 h. Saturated NH4Cl ( 6 mL) was then added 
with the stirring for 0.5 h at rt. After separating the layers, the aqueous phase was 
extracted with DCM (5 mL) and the combined organic layers were washed with H2O 
(5 mL) and saturated NaCl (5 mL), dried over MgSO4, filtered, and concentrated in 
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vacuo. The crude product was purified by silica gel flash column chromatography (3:7 
EtOAc/hexanes, Rf= 0.3), to afford the desired product 11a as a pale yellow oil.  
Representative Procedure for the Ugi Reaction of α-Mesyloxyketones 2 with 
Primary Amines.  
Compound 15a: To a solution of α-mesyloxyketone 2a (48 mg, 0.2 mmol, 1equiv) in 
anhydrous 2,2,2-trifluoroethanol (0.5 mL) at 0 °C was added benzylamine (178 µL, 
0.8 mmol, 4.0 equiv) dropwise. The reaction mixture was stirred for 10 min at 0 °C, 
then acetic acid (23 µL, 0.4 mmol, 2.0 equiv) and cyclohexyl isonitrile (27 µL, 0.22 
mmol, 1.1 equiv) were added via syringe with stirring. The reaction mixture was then 
warmed to rt and stirred for 18 h. The solvent was removed in vacuo. The residula oil 
was  purified by silica gel flash column chromatography (3:7 EtOAc/hexanes,, Rf= 0.3) 
to afford 15a as a white solid (57 mg, 71%) 
Representative Procedure for the Synthesis of Di-O-acylglyceramides.  
Compound 20b: A mixture of acetic acid (57 μL, 1.0 mmol) and Cu(acac)2 (2.6 mg, 
0.01 mmol, 1 mol %) toluene (2 mL) in a 10 mL round-bottom flask was heated to 60 
°C for 10 min under nitrogen. To it was added dropwise a solution of diazoketone 1a 
(226 mg, 1.3 mmol, 1.3 equiv) in toluene (2 mL). Once gas evolution was judged 
complete, the reaction mixture was stirred an additional 5 min, then cooled and 
concentrated in Vacuo. The oily residue was blanketed in nitrogen, then treated with 
isobutyric acid (140 μL, 1.5 mmol, 1.5 equiv) and t-BuNC (170 μL, 1.5 mmol, 1.5 
equiv). The resulting reaction mixture was stirred at rt under N2 for 20 h. The product 
was purified by silica gel flash column chromatography (1:1 EtOAc:hexanes, Rf ) 0.3) 
to afford 5b (338 mg, 90%) as a pale-yellow oil. 
Representative Procedure for the Passerini Reaction of α-Sulfonylketones 7. 
Compound 32d: To a stirred solution under N2 of freshly dried phenylsulfonylacetone 
7b (67 mg, 0.34 mmol) in CH2Cl2 (0.02 mL, 19 M) was added isobutyric acid (37 μL, 
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0.37 mmol) followed by cyclohexylisonitrile (45.5 μL, 0.37 mmol). The reaction 
mixture was stirred at rt for four days, then volatile residues were removed under 
reduced pressure. After TLC analysis,31 the product was purified by silica gel flash 
chromatography (2:1 ethyl acetate:hexanes, Rf ) 0.5) to furnish pure 32d (92 mg, 69%) 
as a colorless oil. 
Representative Procedure for the Ugi Reaction of α-Sulfonylketones 7.  
Compound 33a: A solution of NH4OAc (101 mg, 1.31 mmol) and freshly dried 
phenylsulfonylacetone 7b (65 mg, 0.33 mmol) in anhydrous 2,2,2-trifluoroethanol 
(add vol, 0.4 M) under N2 was stirred at 0 °C for 1 h. The, t-butyl isonitrile (41 μL, 
0.36 mmol) was added and stirring at rt was continued for two days. Volatiles were 
removed under reduced pressure, and after TLC analysis,31 the crude oily product was 
purified by silica gel flash chromatography (10:1 ethyl acetate: hexanes, Rf 0.3) to 
furnish pure 33a (60 mg, 54% yield) as a white solid (mp 175-176 °C). 
IR, MS and Other Physical Characterization Data for New Products 
Mesylate 9a: The crude product was purified by silica gel flash column 
chromatography (3:7 ethyl acetate: hexanes, Rf= 0.2), to afford the desired product as 
a pale yellow oil (68 mg, 88%): IR (CH2Cl2) 3435(s), 2964(s), 1748(s), 1672(s), 
1523(s); CIMS (methane) m/z 386 (M+H), 344, 326, 290, 266.  
Mesylate 9b: The crude product was purified by silica gel flash column 
chromatography (3:7 ethyl acetate: hexanes, Rf= 0.2), to afford the desired product as 
a pale yellow oil (82%): IR (CH2Cl2) 3399(s), 2934(s), 1725(s), 1655(s), 1520(s); 
CIMS (methane) m/z 474 (M+H), 396, 378, 352, 256. 
Mesylate 9c: The crude product was purified by silica gel flash column 
chromatography (1:1 ethyl acetate: hexanes, Rf= 0.3), to afford the desired product as 
a clear oil (80%): IR (CH2Cl2) 3399(s), 2934(s), 2854(s), 1748(s), 1665(s), 1526(s); 
CIMS (methane) m/z 412 (M+H), 370, 334, 316, 256. 
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Mesylate 9d: The crude product was purified by silica gel flash column 
chromatography (3:7 ethyl acetate: hexanes, Rf= 0.3), to afford the desired product as 
a white solid (91%): IR (CH2Cl2) 3349(s), 2934(s), 2851(s), 1748(s), 1659(s), 1532(s); 
CIMS (methane) m/z 406 (M+H), 364, 346, 310, 268. 
Mesylate 9e : The crude product was purified by silica gel flash column 
chromatography (3:7 ethyl acetate: hexanes, Rf= 0.1), to afford the desired product as 
a pale yellow oil (80%): IR (CH2Cl2) 3405(s), 2934(s), 2868(s), 1715(s), 1655(s), 
1532(s); CIMS (methane) m/z 426 (M+H), 376, 348, 330, 208. 
Mesylate 9f: The crude product was purified by silica gel flash column 
chromatography (3:7 ethyl acetate: hexanes, Rf= 0.1), to afford the desired product as 
a pale yellow oil (18%): IR (CH2Cl2) 3380(s), 3059(m), 2931(s), 2850(s), 1752(s), 
1668(s),1521(s); CIMS (methane) m/z 384 (M+H), 342, 324, 288, 246. 
Tosylate 10a: The crude product was purified by silica gel flash column 
chromatography (1:1 ethyl acetate: hexanes, Rf= 0.2), to afford the desired product as 
a pale yellow oil (99%): IR (CH2Cl2) 3438(s), 3388(m), 2967(s), 2924(s), 1725(s), 
1685(s),1519(s); CIMS (methane) m/z 524 (M+H), 447, 402, 370, 352. 
Tosylate 10b: The crude product was purified by silica gel flash column 
chromatography (3:7 ethyl acetate: hexanes, Rf= 0.2), to afford the desired product as 
a pale yellow oil (97%): IR (CH2Cl2) 3442(s), 3385(s), 3342(s, )2931(s), 2854(s), 
1725(s), 1669(s),1516(s); CIMS (methane) m/z 550 (M+H), 378, 350, 286. 
Tosylate 10c: The crude product was purified by silica gel flash column 
chromatography (3:7 ethyl acetate: hexanes, Rf= 0.2), to afford the desired product as 
a pale yellow oil (97%): IR (CH2Cl2) 3396(s), 3339(s), 2927(s), 2851(s), 1745(s), 
1659(s); CIMS (methane) m/z 482 (M+H), 440, 422, 338, 310, 268. 
Tosylate 10d: The crude product was purified by silica gel flash column 
chromatography (3:7 ethyl acetate: hexanes, Rf= 0.2), to afford the desired product as 
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a pale yellow oil (100%): IR (CH2Cl2) 3332(s), 2927(s), 2854(s), 1728(s), 
1662(s),1526(s); CIMS (methane) m/z 544 (M+H), 447, 400, 372. 
Tosylate 10e: The crude product was purified by silica gel flash column 
chromatography (3:7 ethyl acetate: hexanes, Rf= 0.2), to afford the desired product as 
a clear oil (80%): IR (CH2Cl2) 3442(s), 3392(s), 2931(s), 2857(s), 1742(s), 
1675(s),1526(s); CIMS (methane) m/z 440 (M+H), 398, 380, 268, 244. 
Tosylate 10f: The crude product was purified by silica gel flash column 
chromatography (1:1 ethyl acetate: hexanes, Rf= 0.1), to afford the desired product as 
a white solid (28%): IR (CH2Cl2) 3283(s), 2914(s), 2847(s), 1728(s), 1678(s),1652(s); 
CIMS (methane) m/z 522 (M+H), 504, 454, 400, 378, 350. 
β-Lactam 11a: The crude product was purified by silica gel flash column 
chromatography (3:7 ethyl acetate: hexanes, Rf= 0.3), to afford the desired product as 
a pale yellow oil (62%): IR (CH2Cl2) 3053(s), 2927(s), 2857(s), 1751(s); CIMS 
(methane) m/z 344, 316 (M+H), 274, 246, 112. 
β-Lactam 11b: The crude product was purified by silica gel flash column 
chromatography (3:7 ethyl acetate: hexanes, Rf= 0.4), to afford the desired product as 
a pale yellow oil (46%): IR (CH2Cl2) 2967(s), 1758(s), 1725(s),1599(s); CIMS 
(methane) m/z 380, 352 (M+H), 296, 268. 
β-Lactam 11c: The crude product was purified by silica gel flash column 
chromatography (3:7 ethyl acetate: hexanes, Rf= 0.4), to afford the desired product as 
a pale yellow oil (59%): IR (CH2Cl2) 2930(s), 2851(s), 1755(s), 1719(s), 1277(s); 
CIMS (methane) m/z 406, 378 (M+H), 352, 267. 
β-Lactam 11d: The crude product was purified by silica gel flash column 
chromatography (3:7 ethyl acetate: hexanes, Rf= 0.3), to afford the desired product as 
a clear oil (64%): IR (CH2Cl2) 2920(s), 2864(s), 1754(s), 1453(s), 1373(s); CIMS 
(methane) m/z 338, 310 (M+H), 268, 250. 
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β-Lactam 11e: The crude product was purified by silica gel flash column 
chromatography (3:7 ethyl acetate: hexanes, Rf= 0.5), to afford the desired product as 
a clear oil (56%): IR (CH2Cl2) 2927(s), 2854(s), 1755(s), 1722(s); CIMS (methane) 
m/z 400, 372 (M+H), 344, 261. 
Ugi Product 15a: The crude product was purified by silica gel flash column 
chromatography (3:7 ethyl acetate: hexanes, Rf= 0.3), to afford the desired product as 
a white solid (71%): IR (CH2Cl2) 3350(s), 2931(s), 1740(s), 1664(s), 1516(s); CIMS 
(methane) m/z 423 (M+H), 363, 296, 258. 
Ugi Product 15b: The crude product was purified by silica gel flash column 
chromatography (3:7 ethyl acetate: hexanes, Rf= 0.4), to afford the desired product as 
a white solid (66%): IR (CH2Cl2) 3367(s), 2936(s), 1734(s), 1660(s), 1512(s); CIMS 
(methane) m/z 401 (M+H), 383, 339, 313, 284. 
Ugi Product 15c: The crude product was purified by silica gel flash column 
chromatography (3:7 ethyl acetate: hexanes, Rf= 0.3), to afford the desired product as 
a white solid (67%): IR (CH2Cl2) 3362(s), 2930(s), 1722(s), 1670(s), 1514(s); CIMS 
(methane) m/z 453 (M+H), 435, 362, 352. 
Ugi Product 15d: The crude product was purified by silica gel flash column 
chromatography (3:7 ethyl acetate: hexanes, Rf= 0.4), to afford the desired product as 
a white solid (61%): IR (CH2Cl2) 3365(s), 2930(s), 1734(s), 1665(s), 1514(s); CIMS 
(methane) m/z 395 (M+H), 377, 307, 268, 252. 
Ugi Product 15e: The crude product was purified by silica gel flash column 
chromatography (3:7 ethyl acetate: hexanes, Rf= 0.3), to afford the desired product as 
a white solid (39%): IR (CH2Cl2) 3388(s), 2970(s), 2933(s), 1735(s), 1652(s), 1529(s); 
CIMS (methane) m/z 369 (M+H), 351, 314, 278, 213. 
Ugi Product 15f: The crude product was purified by silica gel flash column 
chromatography (3:7 ethyl acetate: hexanes, Rf= 0.2), to afford the desired product as 
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a white solid (74%): IR (CH2Cl2) 3352(s), 3055(s), 2985(s), 1740(s), 1672(s), 1514(s); 
CIMS (methane) m/z 307 (M+H), 247, 206. 
Ugi Product 17a: The crude product was purified by silica gel flash column 
chromatography (1:1ethyl acetate: hexanes, Rf= 0.1), to afford the desired product as a 
pale yellow solid (67%): IR (CH2Cl2) 3422(s), 3329(s), 2924(s), 2851(s), 1742(s), 
1649(s), 1526(s); CIMS (methane) m/z 493, 465 (M+H), 403, 375. 
Product 18a: The crude product was purified by silica gel flash column 
chromatography (1:1 ethyl acetate: hexanes, Rf= 0.2), to afford the desired product as 
a clear oil (60%): IR (CH2Cl2) 3346(s), 2924(s), 2850(s), 1648(s), 15525(s); CIMS 
(methane) m/z 381 (M+H), 349, 282, 254. 
Ugi Product 21a: The crude product was purified by silica gel flash column 
chromatography (3:7 ethyl acetate: hexanes, Rf= 0.1), to afford the desired product as 
a white solid (85%): IR (CH2Cl2) 3425(s), 3338(s), 3055(s), 2985(s), 1672(s), 1497(s); 
CIMS (methane) m/z 235 (M+H), 199, 162. 
Ugi Product 21b: The crude product was purified by silica gel flash column 
chromatography (1:1 ethyl acetate: hexanes, Rf= 0.1), to afford the desired product as 
a white solid (85%): IR (CH2Cl2) 3425(s), 3055(s), 1670(s), 1506(s); CIMS (methane) 
m/z 261 (M+H), 225, 162. 
Passerini Product 22: The crude product was purified by silica gel flash column 
chromatography (1:1 ethyl acetate: hexanes, Rf= 0.5), to afford the desired product as 
a pale yellow oil (10%): IR (CH2Cl2) 3439(s), 3055(s), 2985(s), 1749(s), 1676(s), 
1421(s); CIMS (methane) m/z 262 (M+H), 220, 202. 
Ugi Product 28: The crude product was purified by silica gel flash column 
chromatography (1:1 ethyl acetate: hexanes, Rf= 0.2), to afford the desired product as 
a clear oil (33%): IR (CH2Cl2) 3352(s), 3053(s), 2987(s), 1711(s), 1668(s), 1648(s), 
1638(s); CIMS (methane) m/z 305 (M+H), 287, 249, 205. 
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Ugi Product 29: The crude product was purified by silica gel flash column 
chromatography (1:1 ethyl acetate: hexanes, Rf= 0.3), to afford the desired product as 
a pale yellow oil (49%): IR (CH2Cl2) 3389(s), 2970(s), 2934(s), 1735(s), 1652(s); 
CIMS (methane) m/z 194 (M+H), 178, 166, 138. 
Ugi Product 30: The crude product was purified by silica gel flash column 
chromatography (3:7 ethyl acetate: hexanes, Rf= 0.3), to afford the desired product as 
a pale yellow oil (74%): IR (CH2Cl2) 3442(s), 3026(s), 2967(s), 2107(s), 1748(s), 
1679(s), 1523(s); CIMS (methane) m/z 333 (M+H), 305, 245. 
Ugi Product 31: The crude product was purified by silica gel flash column 
chromatography (7:3 ethyl acetate: hexanes, Rf= 0.2), to afford the desired product as 
a white solid (44%): IR (CH2Cl2) 3422(s), 3363(s), 3053(s), 2981(s), 2107(s), 1675(s); 
CIMS (methane) m/z 242 (M+H), 214, 200,169. 
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CHAPTER FIVE 
Future Direction: Synthesis of Caged Gamma-Aminobutyric Acid and  
Caged Carbamoylcholine Chloride  
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5.1 Background  
The protection of biological molecules by conversion into inactive photolabile 
derivatives (caged precursors) has received increased attention in cell biology. Because 
their deprotection only requires light and very mild conditions, caging groups are widely 
used in the controlled delivery of bioactive molecules with high temporal and spatial 
precision without physically disturbing biological systems.1  
During the last 40 years, caged neurotransmitters have become a powerful tool in 
transient kinetic investigations of the mechanism of action of neurotransmitter receptors.2 
Neurotransmitters are small organic molecules essential for the transmission of signals in 
the central nervous system (CNS). As chemical signal carriers, neurotransmitters are used 
to relay, amplify and modulate electrical signals between neurons and other cells by 
reacting with neurotransmitter receptors. These neurotransmitter receptors exhibit distinct 
kinetic and pharmacological profiles, which are important to the study of many 
neurological disorders in the CNS.  
To investigate the kinetics and mechanism of neurotransmitter receptors, and how 
mutations affect receptor ligand interactions, biologically inert caged neurotransmitter 
precursors have been developed by covalently bonding neurotransmitters to photolabile 
protecting groups. The rapid release (in the microsecond domain) of biologically active 
neurotransmitters by photolysis is capable of providing the time resolution necessary for 
the investigation of the fast processes involved in activation and inhibition of 
neurotransmitter receptors.3
Our effort focused on developing caged neurotransmitters for the two most 
common neurotransmitter receptors, the gamma-aminobutyric acid (GABA) receptor and 
the acetylcholine receptor. GABA is an amino acid and the main inhibitory 
neurotransmitter in the CNS. GABA receptors have been linked to epilepsy, sleep 
disorders, and Parkinson’s disease.2 Acetylcholine is an ester of acetic acid with choline, 
and functions both in the CNS and the peripheral nervous system (PNS) as a 
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neuromodulator. The acetylcholine receptor has been associated with myasthenia gravis 
and Alzheimer's disease.4
 Traditional caged neurotransmitters are released upon irradiation with UV-light 
source, which requires expensive lasers and special safety precautions. Another important 
drawback of UV sensitive caged neurotransmitters is that only 2 or 3 measurements can 
be made on each cell before the cell dies from the damage caused by high-energy UV 
exposure. To circumvent these problems, Hess et al developed a new caging group for 
carboxyl-containing neurotransmitters that is activated in the visible wavelength region. 
7-(N,N-diethylamino)-4-(hydroxymethyl) coumarin (DECM) caged glutamate 5.1 was 
synthesized and photolyzed rapidly and efficiently at 400 nm (Scheme 5.1).3 
 
 
 
Scheme 5.1 Photolysis of DECM-Caged Glutamate  
  
Compound 5.1 was successfully used in a study of the GluR6 glutamic acid 
receptor. Both the DECM-glutamate and its photolytic byproducts were shown to be 
biologically inert to the glutamic acid receptors. To study GABA receptors with the same 
technique, the corresponding caged GABA precursor 5.2 (Figure 5.1) was recently 
synthesized. Compound 5.2 released GABA upon photolysis; however, 5.2 interfered 
with the channel-opening process of the wild-type GABA receptor.  
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Figure 5.1 Caged GABA Compounds of Interest 
To avoid this undesired biological activity, we devised an alternative 
multicomponent route to a family of carboxy-substituted DECM-GABA derivatives, 
represented by compound 5.3. Preliminary biological study of compound 5.3 showed a 
high quantum yield for decaging using 400 nm light. Moreover, both 5.3 and its 
photolysis byproducts were inert towards the GABA receptors. 
Caging acetylcholine posed a challenge because it lacked a functional group that 
could be chemically modified. A stable cholinergic agonist, carbamoylcholine chloride 
5.4 (Scheme 5.2), was chosen in the acetylcholine receptor study. Carbamoylcholine, also 
known as carbachol (marketed under the brand names Carbastat, Carboptic, Isopto 
Carbachol, Miostat), is a choline ester and a positively charged quaternary ammonium 
compound that binds and activates the acetylcholine receptor.5 
 
 
Scheme 5.2 Caged Carbamoylcholine Chloride 
Prior to our study, there was no published report of a DECM caged carbamate or 
amide. Previous investigations suggested that an ester linkage was desired between the 
DECM and carbamoylcholine to enable decaging in high quantum yield. However, a 
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direct ester linkage between carbamoylcholine and DECM was not possible in this case.  
Therefore, an indirect linkage was designed between the carbamoylcholine and DECM 
caging group through an imidodicarbonate (Scheme 5.2). Our expectation was that after 
photolysis, the resulting hydrogen iminodicarbonate would afford carbamoylcholine by 
releasing CO2. Therefore a highly convergent one-pot synthesis of the DECM caged 
carbamoylcholine chloride 5.5 was developed to test this hypothesis.  
5.2 Synthesis of Caged GABA  
 A multicomponent approach to the target compound was devised using the 
Passerini reaction, which affords α-acyloxyesters from the condensation of simple 
aldehydes with carboxylic acids and isonitriles. The known aldehyde 5.6, prepared by 
selenium dioxide oxidation of 7-(N,N-diethylamino)-4-methyl coumarin,2 underwent a 
smooth 3-component condensation with ethyl isocyanoacetate and BOC-protected GABA 
to afford the acyloxydiester 5.7 in 96% yield (Scheme 5.3).  Similar reaction of 5.7 and 
BOC-protected GABA with t-butyl isonitrile and o-tolylisonitrile afforded caged GABA 
derivatives 5.8 and 5.9, respectively. Compounds 5.7-5.9 were purified by flash 
chromatography in the dark for full structural characterization.  
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Scheme 5.3 Synthesis of Caged GABA Compounds 
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The desired caged GABA compounds 5.3, 5.10, and 5.11 were then obtained by 
removing the BOC protecting group upon treatment with TFA. Residual free GABA was 
removed by flash chromatography in the absence of light.  
5.3 Synthesis of Caged Carbamoylcholine Chloride  
A highly convergent one-pot approach from the known alcohol 5.12 to the target 
compound 5.5 was developed (Scheme 5.4). The alcohol 5.12 was prepared by reduction 
of DECM aldehyde 5.6 with sodium borohydride in EtOH.2  
Carbamates were known to form the corresponding acylisocyanate upon treatment 
with oxalyl chloride. The resulting isocyanates are highly reactive intermediates and 
usually used immediately in situ to couple with nucleophiles such as alcohols or amines. 
In most cases, this reaction was carried out in DCM or 1,2 dichloroethane.6 However, 
carbamoylcholine 5.4, as a quaternary ammonium salt, was soluble only in water, 
dimethylformamide and dimethyl sulfoxide, none of which was compatible with oxalyl 
chloride. After careful screening of various organic solvents and conditions, the 
carbamoylcholine acylisocyanate 5.13 was prepared by reacting carbamoylcholine 
chloride 5.4 with oxalyl chloride in refluxing MeCN for 6 h.  
Excess oxalyl chloride and solvent was then immediately removed in vacuo by 
continuously pumping the reaction flask with a standard high vacuum oil pump for 30 
min. The complete removal of oxalyl chloride was necessary to ensure good yield 
because oxalyl chloride reacts more readily with alcohol 5.12 than isocyanate 5.13 does 
and the HCl generated in such side reactions further diminishes the yield by catalyzing 
the decomposition of the imidodicarbonate 5.5. After pumping, the resulting crude grey 
solid 5.13 was dissolved again in fresh MeCN and used immediately in the next step 
without purification.   
 Compound 5.13 underwent a smooth coupling reaction with the alcohol 5.12 to 
afford the desired imidodicarbonate 5.5. After removing solvent in vacuo, the crude 5.5 
 79
as a black solid was purified by tandem flash column chromatography in the dark to yield 
pure 5.5 as a yellow solid for full structural characterization.  
 
 
 
Scheme 5.4 Synthesis of Caged Carbamoylcholine Chloride 5.5 
 
5.4 Conclusion 
 Photolabile DECM-caged GABA compounds ( 5.3, 5.10, 5.11) and 
carbamoylcholine chloride 5.5 were synthesized from readily available starting materials. 
Care was taken to protect the caged neurotransmitters and their derivatives from light, 
particularly when handling aqueous solutions. The caged compounds were sufficiently 
soluble in water and buffers and were stable in the dark when stored cold. Upon exposure 
to visible light, both caged precursors released bioactive neurotransmitter rapidly and 
efficiently. Caged carbamoylcholine 5.5 represents the first DECM caged carbamate and 
the first DECM caged agonist for acetylcholine receptor. This new method has the 
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potential to introduce photolabile protecting groups that can be deprotected in the visible 
wavelength region.  
Caged neurotransmitters are important tools in elucidating the mechanism of 
neurotransmitter receptors. On the basis of their mechanism of action, therapeutic agents 
are being developed to alleviate symptoms caused by dysfunctional receptors in many 
neurological disorders. With these visible-light-sensitive caged neurotransmitters, simple-
to-use, readily available inexpensive light sources can now be applied in transient kinetic 
investigations of a wide range of neurotransmitter receptors, thereby opening up this 
important field to an increasing number of investigators.     
5.5  Experimental Procedures 
1H NMR and 13C NMR were taken on a Varian Inova-400 or Varian Inova-500 
spectrometer as indicated using D2O and CDCl3 with 0.05% v/v TMS as solvent. Spectra 
were recorded in δ (ppm) and were referenced to TMS (0.00 ppm for 1H NMR), H2O 
(4.80ppm for 1H NMR) and CDCl3 (77.23 ppm for 13C NMR). IR spectra were obtained 
on a Thermo Nicolet Avatar 370 DTGS spectrometer and were recorded in wavenumbers 
(cm-1). Chemicals were obtained from Aldrich, Fluka, Fisher, Mallinckrodt and used as 
received unless specified.  
Representative experimental procedure for the synthesis of Passerini compounds 5.7, 
5.8, 5.9. 
Compound 5.7: coumarin aldehyde (50 mg, 0.2 mmol, 1 equiv) was dissolved with 0.2 
mL DCM in a 5 mL round bottom flask.  It was blanketed in nitrogen and covered with 
Al foil. To it was added 4-(Boc-amino)butyric acid (40 mg, 0.2 mmol, 1 equiv) and ethyl 
isocyanoacetate (22 µL, 0.2 mmol, 1 equiv). The resulting homogeneous mixture was 
stirred at rt in dark for 18 h. The product was concentrated in vacuo and purified by flash 
column chromatography in dark (1:1 EtOAc/hexanes, then EtOAc, Rf=0.1) to afford 5.7 
( 101 mg, 90%) as a yellow solid. 1H NMR (400 MHz, CDCl3) δ 8.18 (t, 1 H), 7.61 (d, 1 
H), 6.56 (d, 1 H), 6.40 (s, 1 H), 6.33(s, 1 H), 6.19 (s, 1 H), 5.26 (t, 1 H), 4.04 (dd, 2 H), 
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3.92 (td, 2 H), 3.33 (dd, 2 H), 3.15 (m, 1 H), 3.06 (m, 1 H), 2.51 (m, 1 H), 2.40 (m, 1 H), 
1.80 (m, 1 H) 1.71 (m, 1 H), 1.33 (s, 9 H), 1.09 (m, 9 H); 13C NMR (100 MHz, CDCl3) δ 
171.03, 168.90, 166.90, 161.63, 156.47, 156.21, 149.35, 126.41, 108.79, 107.65, 97.27, 
79.05, 71.11, 61.14, 44.70, 41.04, 38.91, 30.62, 28.24, 25.42,13.98, 12.31; IR (CH2Cl2) 
3336(s), 2977(s), 2937(s), 1742(s), 1682(s), 1619(s), 1596(s); MS (ESI) m/z: 562.2 
(M+H), 506.2. 
Compound 5.8: 1H NMR (400 MHz, CDCl3) δ 7.78 (d, 1 H), 6.61 (d, 1 H), 6.48 (d, 1 H), 
6.33 (d, 1 H), 6.17 (s, 1 H), 6.12 (s, 1 H), 4.79 (s, 1 H), 3.42 (dd, 4 H), 3.20 (m, 2 H), 
2.55 (m, 2 H), 1.88 (m, 2 H), 1.44 (s, 9 H), 1.34 (s, 9 H), 1.20 (t, 6 H); 13C NMR (100 
MHz, CDCl3) δ 171.29, 169.88, 169.87, 165.36, 162.11, 156.74, 156.28, 150.95, 150.48, 
126.77, 109.94, 109.01, 106.87, 106.48, 97.68, 79.49, 71.79, 52.15, 44.89, 39.55, 31.32, 
28.70, 28.53, 25.61, 12.58; IR (CH2Cl2) 3345(s), 3066(m), 2980(s), 2927(s), 1708(s), 
1615(s); MS (ESI) m/z: 532.2 (M+H), 476.2, 338.2. 
Compound 5.9: 1H NMR (400 MHz, CDCl3) δ 8.78 (s, 1 H), 7.78 (d, 1 H), 7.42 (d, 1 H), 
7.06-7.20 (m, 3 H), 6.59 (d, 1 H), 6.46 (d, 2 H), 6.27 (s, 1 H), 4.82 (s, 1 H), 3.40 (dd, 4 H), 
3.29 (s, 1 H), 3.17 (m, 1 H), 2.62 (m, 1 H), 2.54 (m, 1 H), 2.19 (s, 3 H), 1.95 (m, 1 H), 
1.80 (m, 1 H), 1.33 (s, 9 H), 1.19 (t, 6 H); 13C NMR (100 MHz, CDCl3) δ 171.10, 165.27, 
162.26, 156.95, 156.81, 151.17, 150.17, 134.80, 132.42, 130.87, 127.13, 126.84, 126.81, 
125.45, 109.28, 107.45, 106.65, 97.96, 95.41, 79.98, 72.31, 45.25, 39.59, 31.39, 28.75, 
26.22, 18.27, 12.99; IR (CH2Cl2) 3312(s), 2970(s), 2937(s), 1647(s), 1711(s), 1612(s), 
1592(s); MS (ESI) m/z: 566.3 (M+H), 532.3. 
Representative experimental procedure for the synthesis of DECM caged GABA 
compounds 5.3, 5.9, 5.10 
Compound 5.3: Passerini product 1 (20 mg, 0.036 mmol, 1 equiv) was dissolved with 0.5 
mL chloroform in a 5 mL round bottom flask under nitrogen and the flask was wrapped 
with Al foil. To it was added TFA (100 µL, 2.7 mmol, 30 equiv) via syringe. The 
resulting homogeneous mixture was stirred at rt in dark for 18 h. The concentrated crude 
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compound was dissolved in H2O (0.2 ml) in dark and transferred onto silica column. It 
was washed with H2O (20 mL) followed by acetonitrile (20 mL), then eluted with 
acetonitrile with 0.5% v/v TFA (20 mL). The last eluent was concentrated and 
lyophilized to afford 5.3 (12.3 mg, 60%) as a yellow solid. 1H NMR (500 MHz, D2O) δ 
8.07 (d, 1 H), 7.57 (d, 1 H), 7.47 (dd, 1 H), 6.74 (s, 1 H), 6.43 (s, 1 H), 3.98 (dd, 2 H), 
3.91 (s, 2 H), 3.59 (dd, 4 H), 2.93 (t, 2 H), 2.60 (m, 2 H), 1.89 (m, 2 H), 1.58-1.75 (m, 3 
H), 1.01 (m, 9 H); 13C NMR (125 MHz, D2O) δ 172.54, 170.95, 168.43, 161.75, 154.21, 
148.47, 140.06, 128.30, 118.88, 118.46, 117.76, 117.47, 115.15, 112.11, 71.98, 62.61, 
54.07, 41.58, 38.66, 30.35, 21.88, 13.34, 9.77; IR (neat) 3080(s), 2980(s), 2951(s), 
1748(s), 1668(s), 1615(s); MS (ESI) m/z: 462 (M+), 377.1. 
Compound 5.10: 1H NMR (500 MHz, D2O) δ 8.12 (d, 1 H), 7.65 (d, 1 H), 7.55 (dd, 1 H), 
6.76 (s, 1 H), 6.36 (s, 1 H), 3.70 (dd, 4 H), 3.03 (t, 2 H), 2.73 (m, 2 H), 2.00 (m, 2 H), 
1.28 (s, 9 H), 1.12 (t, 6 H); 13C NMR (125 MHz, D2O) δ 172.85, 166.63, 162.05, 154.26, 
148.87, 140.25, 127.79, 118.52, 118.19, 117.64, 116.75, 115.32, 111.83, 72.50, 72.46, 
53.83, 52.56, 38.67, 30.42, 27.58, 21.96, 9.86; IR (nujol) 1735(s), 1692(s), 1625(s), 
1376(s); MS (ESI) m/z: 432.2 (M+), 347.1, 216.6. 
Compound 5.11: 1H NMR (500 MHz, D2O) δ 8.26 (d, 1 H), 7.69 (d, 1 H), 7.58 (dd, 1 H), 
7.2-7.3 (m, 3 H), 7.11 (d, 1 H), 6.94 (s, 1 H), 6.68 (s, 1 H), 3.70 (dd, 4 H), 3.06 (t, 2 H), 
2.73 (m, 2 H), 2.03 (m, 2 H), 2.00 (s, 3 H), 1.12 (t, 6 H); 13C NMR (125 MHz, D2O) δ 
172.88, 167.56, 161.99, 154.42, 135.24, 133.18, 131.13, 128.62, 128.15, 127.06, 126.99, 
118.71, 117.47, 112.00, 72.50, 53.91, 38.69, 30.44, 21.99, 16.84, 9.88; IR (neat) 3373(s), 
2973(s), 1748(s), 1665 (s), 1422(s); MS (ESI) m/z: 466.2 (M+), 381.1. 
Experimental procedure for the synthesis of DEAM caged carbamoylcholine 
chloride product 5.5. 
Compound 5.5: Carbamoylcholine chloride (50 mg, 0.275 mmol, 3.5 equiv) was 
suspended with fresh acetonitrile (0.2 mL) in a 10 mL round bottom flask under nitrogen 
and stirred for 5 min at rt. To it was added oxalyl chloride (100 µL, 1.16 mmol, 15 equiv) 
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via syringe. Gas was formed. The mixture was refluxed at 80 °C for 5 hr under N2 
yielding a brown homogeneous mixture. Solvent and excess oxalyl chloride was removed 
by vacuum pump, resulting light brown foam/solid. The solid was dissolved in 
acetonitrile (0.5 mL). Color darkened and the reaction flask was wrapped with Al foil and 
cooled in ice bath. To it was added coumarin alcohol (20 mg, 0.08 mmol, 1equiv) in 
acetonitrile (0.5 mL). The mixture was stirred at rt in dark for 18 h. The crude product 
was concentrated by vacuum pump and the resulting black solid was extracted with H2O 
(3x 1 mL). The aqueous extracts were combined and lyophilized in a foil-covered flask to 
afford brown solid (~ 200mg). The solid was dissolved in MeOH (0.2 ml) in dark and 
transferred onto alumina column (Neutral, Activity I, 10 mL). It was eluted with acetone 
(50mL) followed by MeOH (50 mL). MeOH fractions with positive UV confirmation 
were combined and concentrated in vacuo. The resulting yellow/brown solid was further 
purified by second flash chromatography (Sephadex LH-20, H2O). The eluents that were 
UV positive were concentrated and lyophilized to afford 5.5 (11.3 mg, 31%) as a yellow 
solid. 1H NMR (500 MHz, DMSO-D6) δ 7.45 (d, 1 H), 6.69 (dd, 1 H), 6.55 (d, 1 H), 6.06 
(s, 1 H), 5.34 (s, 2 H), 4.50 (s, 2 H), 3.65 (m, 2 H), 3.43 (q, 4 H), 3.31 (s, 9 H), 1.12 (t, 3 
H); 1H NMR (500 MHz, CD3OD) δ 7.48 (d, 1 H), 6.75 (dd, 1 H), 6.56 (d, 1 H), 6.11 (s, 1 
H), 5.40 (s, 2 H), 4.63 (s, 2 H), 3.76 (m, 2 H), 3.49 (q, 4 H), 3.24 (s, 9 H), 1.89 (t, 3 
H);13C NMR (125 MHz, CD3OD) δ 170.44, 164.49, 157.68, 152.83, 152.72, 126.25, 
110.63, 107.07, 105.96, 98.44, 66.18, 63.71, 60.33, 54.69, 45.78, 12.85; IR (neat) 3362(s), 
2973(s), 1798(s), 1708 (s), 1602 (s); MS (ESI) m/z: 419.8 (M+), 229.9. 
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